

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 01-179	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/786253	
INTERNATIONAL APPLICATION NO PCT/AU00/00805		INTERNATIONAL FILING DATE 03 July 2000 (03.07.00)		PRIORITY DATE CLAIMED 02 July 1999 (02.07.99)	
TITLE OF INVENTION CONTROL OF ACIDOSIS					
APPLICANT(S) FOR DO/EO/US ROWE, James Baber; AL JASSIM, Rafat, A. M.;					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 3713. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau)b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5))					
Items 13 to 20 below concern document(s) or information included:					
<ol style="list-style-type: none">13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.15. <input checked="" type="checkbox"/> A FIRST preliminary amendment.16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.17. <input type="checkbox"/> A substitute specification18. <input type="checkbox"/> A change of power of attorney and/or address letter.19. <input type="checkbox"/> Certificate of Mailing by Express Mail20. <input checked="" type="checkbox"/> Other items or information:					
Patent Data Sheet; Postcard; Check No. 26762 for the Amount of \$988.00; Published PCT Application; 9 Sheets of amended claims as amended in preliminary amendment; 10 sheets of redlined amended claims;					

528 Rec'd PCT/PTO 02 MAR 2001

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/7786233		INTERNATIONAL APPLICATION NO. PCT/AU00/00805		ATTORNEY'S DOCKET NUMBER 01-179	
---	--	--	--	---	--

21. The following fees are submitted:. BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$1,000.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	52 - 20 =	32	x \$18.00	\$576.00	
Independent claims	8 - 3 =	5	x \$80.00	\$400.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,976.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				\$988.00	
SUBTOTAL =				\$988.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$988.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$988.00	
				Amount to be: refunded	\$
				charged	\$

☒ A check in the amount of **\$988.00** to cover the above fees is enclosed.


☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **13-2490** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Michael S. Greenfield
 McDonnell Boehnen Hulbert & Berhoff
 300 South Wacker Drive
 Suite 3200
 Chicago, IL 60606
 United States of America
 Telephone (312) 913 - 0001
 Fax (312) 913 - 0002


 SIGNATURE
 Michael S. Greenfield
 NAME
 37,142
 REGISTRATION NUMBER
 02 March 2001
 DATE

PTO/PCT Rec'd 15 AUG 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-179)

In the Application of:)
)
 Rowe et al.)
) Examiner: Not yet assigned
 Serial No.: 09/786,253)
) Group Art Unit: Not yet Assigned
 Filing Date: March 2, 2001)
)
 For: Control of Acidosis)

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In Response to the Notification To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on April 9,
2001, Applicants request that the Examiner consider the following materials.

AMENDMENT

IN THE SPECIFICATION:

Please replace the originally-filed page 46 with the substitute page 46.

IN THE SEQUENCE LISTING:

Please substitute the originally-filed Sequence Listing with the enclosed amended
Sequence Listing.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington D C 20231, on August 9, 2001

Date: August 9, 2001


Michael S. Greenfield

REMARKS

Specification

Page 46 of the specification was amended to include the appropriate SEQ ID NOs, in compliance with 37 C.F.R § 1.821-1.825. Specifically, (SEQ ID No:8) was added after (5'-AGAGTTTGATCCTGGCTCAG-3'); (SEQ ID No:9) was added after (5'-GGTTACCTTGTTACGACT-3'); (SEQ ID No:10) was added after (5'-GTGCCAGCMGCCGCGG-3'); (SEQ ID No:11) was added after (5'-GWATTACCGCGGCKGCTG-3'); (SEQ ID No:12) was added after (5'-CCGTC AATTCMTTTRAGTTT-3'); and (SEQ ID No:13) was added after (5'-AAACTYAAAKGAATTGACGG-3').

A copy of the marked up original page 46 is attached as Appendix A.

No new matter has been added by way of these amendments to the specification.

SEQUENCE LISTING

Pursuant to the Notification To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures and in compliance with 37 C.F.R § 1.821-1.825, Applicant herewith submit a Sequence Listing in written form and computer readable form (3.5 inch disk).


The Sequence Listing has been amended to include sequences of the primers disclosed at page 46 of the specification and a description of the mandatory data elements for "n" used in sequence of SEQ ID NO:1.

The amended Sequence Listing also includes a description of an unknown organism for sequences of SEQ ID NOs:1-7. Support for this amendment may be found in the specification at page 3, lines 10-12 through page 4, lines 1-4.

The written and computer readable forms of the Sequence Listing are the same and neither form contains new subject matter. The Sequence Listing has been prepared in the PatentIn Ver.2.0 format and checked with Checker Version 3.0 Program. No error has been found.

If there are any questions or comments regarding this Response or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Respectfully submitted,



Michael S. Greenfield

Registration No. 37,142

Date: August 9, 2001

Telephone: 312-913-0001

Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606

PTO/PST Rec'd 15 AUG 2001

WO 01/02008

46

PCT/AU00/00805

Reactions were overlaid with sterile mineral oil and carried out in a thermocycler (Perkin-Elmer DNA Thermal Cycler 480). Thermocycling parameters employed after at 96°C, denaturation for 10 min were 28 cycles of 1 min at 94°C, 1 min at an annealing temperature, and 2 min at 72°C. A further extension step involving 1 min at 48°C and 5 min at 72°C was also employed. The primers used were 27f (5'-AGAGTTTGATCCTGGCTCAG-3') (SEQ ID No:8) and 1492r (5'-GGTTACCTTGTTACGACT-3') (SEQ ID No:9) (Lane 1991). In some cases GeneReleaser (Bioventures Inc., Tennessee, USA) was used according to the manufacturer's instructions in the reactions outlined above. PCR products were purified using a QIAquick PCR purification kit (QIAGEN, Victoria Australia) according to the manufacturer's instructions.

Sequencing of 16S rDNA

All 16S rDNA samples were initially partially sequenced using the universal 16S rRNA primer, 530f (5'-GTGCCAGCMGCCGCGG-3') (SEQ ID No: 10) and an ABI Big Dye Terminator Cycle Sequencing Ready Reaction Mix kit (Victoria, Australia). Selected 16S rDNA were subsequently fully sequenced on both strands using the following primers: 519r (5'-GWATTACCGCGGCKGCTG-3') (SEQ ID No:11), 27f, 907r (5'-CCGTCAATTCMTTTRAGTTT-3') (SEQ ID No:12), 926f (5'-AAACTYAAAKGAATTGACGG-3') (SEQ ID No:13), and 1492r (Lane, 1991).

Approximately 100 ng of purified PCR product and 25 ng of primer were used in the sequencing reactions. Thermal cycling was carried out in an MJ Research PTC-100 thermocycler with an initial denaturation step of 96°C for 2 min, following by 25 cycles of 50°C for 15s, 60°C for 4 min, and 96°C for 30s. The resulting cycle sequencing products were purified using the ethanol plus sodium acetate method (ABI, Australia). Purified sequencing products were submitted to the Australian Genome Research Facility for analysis on an Applied Biosystems 377 automated sequencer.

Phylogenetic analysis

Phylogenetic analysis of 16S rDNA's was carried out according to Dojka et al. (1998). Briefly, sequences were aligned and compiled in SeqEd (Applied Biosystems Australia). Compiled sequences were compared with those on publicly available databases by use of the BLAST (Basic Alignment Search Tool) (Altschul et al. 1990) to determine approximate phylogenetic affiliations. Compiled sequences were then aligned using the ARB software package (Strunk *et al.* unpublished) and refined manually. Phylogenetic trees based on comparative analysis of the 16S rRNA genes were construction by performing evolution distance analyses on these alignments using the

Reactions were overlaid with sterile mineral oil and carried out in a thermocycler (Perkin-Elmer DNA Thermal Cycler 480). Thermocycling parameters employed after at 96°C, denaturation for 10 min were 28 cycles of 1 min at 94°C, 1 min at an annealing temperature, and 2 min at 72°C. A further extension step involving 1 min at 48°C and 5 min at 72°C was also employed. The primers used were 27f (5'-AGAGTTTGATCCTGGCTCAG-3') (SEQ ID No:8) and 1492r (5'-GGTTACCTTGTTACGACT-3') (SEQ ID No:9) (Lane 1991). In some cases GeneReleaser (Bioventures Inc., Tennessee, USA) was used according to the manufacturer's instructions in the reactions outlined above. PCR products were purified using a QIAquick PCR purification kit (QIAGEN, Victoria Australia) according to the manufacturer's instructions.

Sequencing of 16S rDNA

All 16S rDNA samples were initially partially sequenced using the universal 16S rRNA primer, 530f (5'-GTGCCAGCMGCCGCGG-3') (SEQ ID No:10) and an ABI Big Dye Terminator Cycle Sequencing Ready Reaction Mix kit (Victoria, Australia). Selected 16S rDNA were subsequently fully sequenced on both strands using the following primers: 519r (5'-GWATTACCGCGGCKGCTG-3') (SEQ ID No:11), 27f, 907r (5'-CCGTCAATTCMTTTRAGTTT-3') (SEQ ID No:12), 926f (5'-AAACTYAAAKGAATTGACGG-3') (SEQ ID No:13), and 1492r (Lane, 1991).

Approximately 100 ng of purified PCR product and 25 ng of primer were used in the sequencing reactions. Thermal cycling was carried out in an MJ Research PTC-100 thermocycler with an initial denaturation step of 96°C for 2 min, following by 25 cycles of 50°C for 15s, 60°C for 4 min, and 96°C for 30s. The resulting cycle sequencing products were purified using the ethanol plus sodium acetate method (ABI, Australia). Purified sequencing products were submitted to the Australian Genome Research Facility for analysis on an Applied Biosystems 377 automated sequencer.

Phylogenetic analysis

Phylogenetic analysis of 16S rDNA's was carried out according to Dojka et al. (1998). Briefly, sequences were aligned and compiled in SeqEd (Applied Biosystems Australia). Compiled sequences were compared with those on publicly available databases by use of the BLAST (Basic Alignment Search Tool) (Altschul et al. 1990) to determine approximate phylogenetic affiliations. Compiled sequences were then aligned using the ARB software package (Strunk *et al.* unpublished) and refined manually. Phylogenetic trees based on comparative analysis of the 16S rRNA genes were construction by performing evolution distance analyses on these alignments using the

**Redline Claims for U.S. National Phase of
PCT/AU00/00805**

1. A vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.
2. The vaccine of claim 1, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species. *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.
3. (Amended)The vaccine of claim 1 ~~or~~ 2, wherein the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).
4. (Amended)The vaccine of ~~any one of~~ claims 1 ~~to~~ 3, wherein the vertebrate is selected from the group consisting of a monogastric, herbivore, human or ruminant animal.

6. ~~(Amended)~~The vaccine of any one of claims 1 to 4, wherein said vaccine comprises outer membrane and associated proteins of at least one of said microorganisms.

7. (Amended) The vaccine of ~~any one of~~ claims 1 to 6, wherein the fragment or fragments of the microorganism is present in the vaccine as an immunogenic polypeptide, glycopeptide or the like.

8. ~~(Amended)~~ The vaccine of ~~any one of~~ claims 1 to 7, wherein the vaccine is formulated for administration via intramuscular, subcutaneous, inhalation, topical or other parenteral route.

9. A pharmaceutical composition for the prevention of lactic acidosis in a vertebrate comprising at least one isolated microorganism capable of producing lactic acid within the gut of a vertebrate, or fragment or fragments thereof, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

10. The pharmaceutical composition of claim 9, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

11. (Amended) The pharmaceutical composition of claim 9 or 10, wherein the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus*

equinus (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634). *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolates LAB04 (NM00/12633), and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

12. (Amended)The pharmaceutical composition according to ~~any one of claims 9 to 11~~, wherein the microorganism is provided as live cells, attenuated cells, killed whole cells, cell lysate, crude antigen mixture or purified antigen or antigens from the microorganism.

13. (Amended)The pharmaceutical composition according to ~~any one of claims 9 to 12~~, wherein the microorganism, and/or fragment or fragments thereof, is present as outer membrane and associated proteins of said microorganism.

14. (Amended)The pharmaceutical composition according to ~~any one of claims 9 to 13~~, wherein the fragment or fragments of the microorganism is present as an immunogenic polypeptide or glycopeptide, or the like.

15. (Amended)The pharmaceutical composition according to ~~any one of claims 9 to 14~~, further comprising at least one cytokine.

16. (Amended)A method for inducing an immune response against lactic acidosis in a vertebrate, comprising administering to said vertebrate an immunologically effective amount of the vaccine in accordance with ~~any one of claims 1 to 8~~ claim 1, or a pharmaceutical composition in accordance with ~~any one of claims 10 to 15~~ claim 10.

17. A method according to claim 16, further comprising administering at least one cytokine.
18. ~~(Amended)~~ A method for inducing an immune response against lactic acidosis in a vertebrate, comprising administering to said vertebrate an immunologically effective amount of the vaccine according to ~~any one of claims 1 to 8~~ claim 1.
19. ~~(Amended)~~ A method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of the vaccine in accordance with ~~any one of claims 1 to 8~~, or a pharmaceutical composition in accordance with ~~any one of claims 10 to 15~~ claim 10.
20. The method of claim 19, wherein said method further comprises the administration of an active agent.
21. A method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of an active agent capable of preventing or controlling lactic acid accumulation in the gut of a vertebrate, and wherein said lactic acid is produced by at least one microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.
22. The method of claim 21, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species. *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.
23. ~~(Amended)~~ The method of claim 21 ~~or 22~~, wherein said microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1)

(NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

24. (Amended) The method of ~~any one of claims 19 to 23~~, wherein the active agent is used in conjunction with a vaccine according to ~~any one of claims 1 to 8~~.

25. (Amended) The method of ~~any one of claims 19 to 24~~, wherein the active agent is selected from the group consisting of: antibiotics, enzyme preparations, clay preparations, compounds which slow the digesta flow, prebiotics and probiotics.

26. The method of claim 25, wherein the antibiotic is active against gram-positive lactic acid producing microorganisms.

27. The method of claim 25, wherein the enzyme preparation is active against lactic acid producing gram-negative bacteria.

28. The method of claim 25, wherein the clay preparation is active against lactic acid producing Gram-negative or Gram positive bacteria.

29. The method of claim 25, wherein the compounds which slow digesta flow rate are indirectly active against lactic acid producing gram-negative bacteria.

30. The method of claim 29, wherein the compounds which slow digesta flow rate are selected from the group consisting of biologically active peptides (BAP), compounds active on the

autonomic nervous system, 5HT agonists/antagonists, motilin antagonists, NO promoters, and dopamine.

31. The method of claim 25, wherein the probiotic preparations include bacteria selected from the group consisting of: *Megasphaera*, *Veillenolla*, *Selenomonas*, *Propionibacterium*, *Anaerovibrio* and *Peptococcus*.

32. The method of claim 31, wherein the probiotic preparations include yeast and mycelial preparations capable of utilising lactic acid, and converting lactic acid to volatile fatty acids and other end products.

33. An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of: SEQ ID Nos. 1-7.

34. A nucleic acid molecule analogue of the polynucleotide sequence of claim 33, wherein said analogue has at least 85% homology to said polynucleotide sequence.

35. (Amended) A nucleic acid molecule oligonucleotide fragment of the polynucleotide sequence according to claim 33 ~~or 34~~.

36. (Amended) A vector comprising the nucleic acid molecule according to any one of claims 33 ~~to 35~~.

37. The vector of claim 36, wherein the vector is selected from the group consisting of: viral, plasmid, bacteriophage, phagemid, cosmid, bacterial artificial chromosome, and yeast artificial chromosome.

38. (Amended) A host cell transformed with the vector of claim 36 ~~or claim 37~~.

39. An antibody raised against at least one lactic acid producing microorganism, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species. *Prevotella*-like

species, *Bacteroides*-like species. *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

40. The antibody of claim 39, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

41. (Amended)The antibody of claim 39 ~~or 40~~, wherein said microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM0012/635) and LAB08 (NM00/12637).

42. (Amended)A vaccine comprising at least one antibody according to ~~any one of claims 39 to 41~~, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

43. (Amended)A diagnostic kit for the detection of microorganisms having a role in lactic acidosis in a vertebrate, said kit comprising at least one antibody according to ~~any one of claims 39 to 41~~, together with a diagnostically acceptable carrier and/or diluent.

44. (Amended)The diagnostic kit of claim 43 comprising:

- (a) a first container containing at least the antibody (or fragment thereof) according to ~~any one of claims 39 to 41~~ claim 39, and;

- (b) a second container containing a conjugate comprising a binding partner of the antibody (or fragment thereof), together with a detectable label.

45. The diagnostic kit of claim 44, wherein said first container further contains antibodies selected from the group consisting of: antibodies capable of detecting at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli and antibodies capable of detecting *Streptococcus bovis* (strain Sb-5).

46. A method for screening for the presence of microorganisms having a role in acidosis in a vertebrate comprising:

- (a) contacting a sample from the gut of a vertebrate with the antibody (or fragment thereof) according to ~~any one of claims 39 to 41~~ claim 39, and
- (b) detecting the presence of the antibody (or fragment thereof) bound to microorganisms having a role in acidosis.

47. A method for screening for the presence of microorganisms having a role in acidosis in a vertebrate comprising:

- (a) contacting a nucleic acid sample from a microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dexran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, and
- (b) detecting hybridisation between the nucleic acid sample and the probe sequence.

48. (Amended) The method of claim 47 wherein the nucleic acid probe corresponds to a portion of at least one of the polynucleotide sequences ~~according to any one of claims 33 to 34~~ selected from the group consisting of: SEQ. ID. Nos.: 1-7, which is capable of selectively hybridising to nucleic acid from a sample.

49. (Amended)The method of claim ~~47 and 48~~ 47, wherein the nucleic acid probe corresponds to a probe mix, comprising a portion of the polynucleotide sequence ~~according to any one of claims 34 to 35~~ having at least 85% homology to a polynucleotide sequence selected from the group consisting of SEQ. ID. Nos.: 1-7 which is capable of selectively hybridising to nucleic acid from a sample, together with an isolated nucleic acid molecule comprising a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli, or a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of the microorganism strain *Streptococcus bovis* (strain Sb-5).

50. A method for screening for potential therapeutic agents for the treatment of lactic acidosis in a vertebrate, said method comprising

(a) contacting the potential therapeutic agent with a microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, and

(b) detecting an effect of the therapeutic agent on said microorganism.

51. The method of claim 50, wherein said therapeutic agent alters the lactic acid production pathway in at least one of said microorganisms.

52. An isolated culture of at least one microorganism selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01

(NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

WO 01/02008

PCT/JP00/00805

1/7

SEQUENCE LISTING

<110> The University of New England; James Baber Rowe; R.A.M. Al Jassim
 <120> Control of Acidosis
 <130> 467010
 <150> PQ1376
 <151> 2 July 1999
 <160> 7
 <210> 1
 <211> 1498
 <212> DNA
 <213> Bacteria
 <400> 1

```

1  GACGAACGCT GCGGGCGTGC NTAATACATG CAAGTAGAAC GCTGAAGACT
51  TTAGCTTGCT AAAGTTGGAA GAGTTGCGAA CCGGTGAGTA ACGCGTAGGT
101 AACCTGCCTA CTAGCGGGGG ATAACATATTG GAAACCA-TA GCTAATACCG
151 CATA--ACAG CATTTAACAC ATGTTAGATG CTTGAAGGA GC-----A
201 ATT---GCT TCACTAGTAG ATGGACCTGC GTTGTATTAG CTAGTTGGTG
251 AGGTAACGGC TCACCAAGGC GACGATACAT AGCCGACCTG ACAGGGTGAT
301 CCGCCACACT CCGACTGAGA CACGGCCCGAG ACTCCTACGG GAGGCAGCAG
351 TAGGGAATCT TCGGCAATGG GGGCAACCTT GACCGAGCAA CGCCGCGTGA
401 GTGAAGAAGG TTTTCGGATC GTAAAGCTCT GTTGTAGA- GAAGAACGTG
451 TGTGAGAGTG GAAAGTTCAC ACAGTGACGG TAACTTACC- AGAAGGGAC
501 GGCTAACTAC GTGCCAGCAG CCGCGGTAAT ACGTAGGTCC CGAGCGTTGT
551 CCGGATTTAT TGGGCGTAAA GCGAGCGCAG GCGGTTTAAAT AAGTCTGAAG
601 TTAAAGGCAG TGGCTTAACC ATTGTTGCTT TTGGAAACTG TTAGACTTGA
651 GTGCAGAAGG GGAGAGTGGA ATTCATGTG TAGCGGTGAA ATGCGTAGAT
701 ATATGGAGGA ACACCGGTGG CGAAACCGCC TCTCTGGTCT GTAAC TGACG
751 CTGAGGCTCG AAAGCGTGGG GAGCAAACAG GATTAGATAC CCTCGTAGTC
801 CACGCCGTAA ACGATGAGTG CTAGGTGTTA GGCCCT--TT CC--GGGGCT
851 TAGTGCCGCA GCTAACGCAT TAAGCACTCC GCCTGGGGAG TACGACCGCA
901 AGGTTGAAAC TCAAAGGAAT TGACGGGGGG CCG-CACAAG CCGTGAGCA
951 TGTGGTTTAA TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCC
1001 CGATGCTATT CTTAGAGATA GGAAGTT-TC TTCGGA-ACA TCGGTGACAG
1051 GTGGTGCTAT GTTGTCTGTA GCTCGTGTG TGAGATGTTG GGTAAAGTCC
1101 CGCAACGAGC GCAACCCCTA TTGTTAGTTG CCATCAT-TA AG-TTGGGCA
1151 CTCTAGCGAG ACTGCCGGTA ATAAACCGGA GGAAGGTGGG GATCACGTCA
1201 AATCATCATG CCCCTTATGA CCTGGGCTAC ACACGTGCTA CAATGGTTGG
1251 TACAACGAGT CGCGAGTGGG TGACGGCAAG CAAATCTCTT -AAAGCCAAT
1301 CTCAGTTCGG ATTGTAGGCT GCAACTCGCC TACATGAAGT CGGAATCGCT
1351 AGTAATCGCG GATCAGCAGC CCGCGGTGAA TACGTTCCCG GGCTTTGTAC
1401 ACACCGCCCG TCACACCACG AGAGTTTGTG ACACCCGAAG TCGGTGAGGT
1451 AACCT-TT-T GGAGCCAGCC GCCTAAGGTG GGATAGATGA TTGGGGTG
  
```

1000 0000 80 0000 0000

097862509/0786253

WO 01/02008

PCT/AU00/00805

2/7

<130> 467010
<150> PQ1376
<151> 2 July 1999
<210> 2
<211> 1498
<212> DNA
<213> Bacteria
<400> 2

1
51
101
151
201
251
301
351
401
451
501
551 CCGGATTAT TGGGCGTAAA GCGAGCGCAG GCGGTTTAAT AAGTCTCAAG
601 TTAAAGGCAG TGGCTTAACC ATTGTTCTGCT TTGGAAACTG TTAGACTTGA
651 GTGCAGAAGG GGAGAGTGGA ATTCCATGTG TAGCGGTGAA ATGCGTAGAT
701 ATATGGAGCA ACACCGGTGG CGAAAGCGGC ICTCTGGTCT GTAACGACG
751 CTGAGGCTCG AAAGCGTGGG GAGCAAACAG GATTAGATAC CCTGGTAGTC
801 CACGCCGTAA ACGATGAGTG CTAGGTGTTA GGCCCT--TT CC--GGGGCT
851 TAGTGCCGCA GCTAACGCAT TAAGCACTCC GCCTGGGGAG TACGACCGCA
901 AGGTTGAAAC TCAAAGGAAT TGACGGGGCC CCG-CACAAG CGGTGGAGCA
951 TGTGGTTTAA TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCC
1001 CGATGCTATT TCTAGAGATA GGAAGTT-TC TTCGGA-ACA TCGCTCACAG
1051 GTGGTGCATG GTTGTCGTCA GCTCGTGTG TGAGATGTTG GGTAAAGTCC
1101 CGCAACGAGC GCAACCCCTA TTGTTAGTTG CCATCAT-TA AG-TTGGGCA
1151 CTCTAGCCAG ACTGCCGGA ATAAACCGGA GGAAGGTGGG GATGACGTCA
1201 AATCATCATG CCCCTTATGA CCTGG.....
1251
1301
1351
1401
1451

WO 01/02008

PCT/AU00/00805

3/7

<130> 467010
 <150> PQ1376
 <151> 2 July 1999
 <210> 3
 <211> 1498
 <212> DNA
 <213> Bacteria
 <400> 3

```

1 .....
51 .....
101 .....
151 .....
201 .....
251 .....
301 .....
351 .....
401 .....
451 .....
501 .....
551 ....ATTTAT TGGGCGTAAA GCGAGCGCAG GCGGTTTAAT AAGTCTGAAG
601 TTAAAGGCAG TGCTTAACC ATTGTTTCGT TTGGAAACTG TTAGACTTGA
651 GTGCAGAAGG GGAGAGTGCA ATTCCATGTG TAGCGGTGAA ATGCGTAGAT
701 ATATGGAGGA ACACCGGTGG CGAAAGCGGC TCTCTGGTCT GTAAC TGACG
751 CTGAGGCTCG AAAGCGTGGG GAGCAAACAG GATTAGATAC CCTGGTAGTC
801 CACGCCGTAA ACGATGAGTG CTAGGTGTTA GGCCCT--TT CC--GGGGCT
851 TAGTGCCGCA GCTAACGCAT TAAGCACTCC GCCTGGGGAG TACGACCGCA
901 AGGTTGAAAC TCAAAGGAAT TGACGGGGGC CCG-CACAAG CGGTGGAGCA
951 TGTGGTTTAA TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTGACATCC
1001 CGATGCTATT TCTAGAGATA GGAAGTT-TC TTCGGA-ACA TCGGTGACAG
1051 GTGGTGCA TG GTTGTCTCA GCTCGTGTG TCAGATGTTG GGTAAAGTCC
1101 CGCAACGAGC GCAACCCCTA TTGTTAGTTG CCATCAT-TA AG-TTGGGCA
1151 CTCTAGCGAG ACTGCCGCTA ATAAACCGCA GGAAGGTGGG GATGACGTCA
1201 AATCATCATG CCCCTTATGA CCTGG.....
1251 .....
1301 .....
1351 .....
1401 .....
1451 .....
```

WO 01/02008

PC J00/00805

4/7

<130> 467010
 <150> PQ1376
 <151> 2 July 1999
 <210> 4
 <211> 1498
 <212> DNA
 <213> Bacteria
 <400> 4

```

1  GATGAACGCT GGC GGCGTGC CTAATACATG CAAGTCGAAC GGGG-----
51  -ATCTTCGGA T-----TC CAGTGGCGAA CGGGTGAGGA ATACATAGGT
101 AACCTGCCCC TCCGAGGGGG ACAACAGACG GAAACATCTG -CTAAGACCG
151 CATAG-C-CA CAGGGAAGGC ATCTTCCTG TGCCTAATGT CCTT-----T
201 CG-----GGGA CAGCGGGGGG ATGGACCTAT GCCGCATTAG CTGGTTGGCG
251 GGGCAACGGC CCACCAAGGC GACGATGCGT AGCCGGCCTG AGAGGGCGGA
301 CGGCCACACT GGGACTGAGA CACGGCCCGAG ACTCCTACGG GAGGCAGCAG
351 TAGGGAATTT TCGGCAATGG GGGAAACCTT GACCGAGCAA CGCCGCGTGA
401 ACGATGAAGG CCTTCGGGTC GTAAAGTTCT GTTGC-GAAG GAAGAACGCC
451 GGTGTCAGCA AA-TGGGCGC CGGGTGACGG TACTTCGCAT AGAAAGCCAC
501 GGCTAACTAC GTGCCAGCAG CCGCGTAAT ACGTAGGTGG CGAGCGTTAT
551 CCGGAATCAT TGGGCGTAA GAGGGAGCAG GCGGCGATAC AGGTCTGTGG
601 TGAAATTCCG AAGCTAACT TCGGCCAGCC AAAGAAACCG GATCGCTAGA
651 GTGCGGAAGA GGATCGTGGA ATTCCATGTG TAGCGGTGAA ATGCGTAGAT
701 ATATGGAGGA ACACCAGTGG CGAAGGCGAC GGTCTGGGCC GCAACTGACG
751 CTCATTCCCG AAAGCGTGGG GAGCAAATAG GATTAGATAC CCTAGTAGTC
801 CACGCCGTAA ACGATCGATA CTAAGTGTGG GGGG-----TC AA-----ACCT
851 CGGTGCTGGA GTCAACGCAA TAAGTATCGC GCCTGAGTAG TACGTTGCGA
901 AGAATGAAAC TCAAAGGAAT TGACGGGGGG CCGC-ACAAG CGGTGGAGCA
951 TGTCTTTTAA TTCCAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCG
1001 ATCCAAAAGG GACGGAGACG TCCCCA---T AGCTA---TG GAGAAGACAG
1051 GTGGTGCATG GTTGTCTGCA GCTCGTGTGG TGAGATGTTG GCTTAAGTCC
1101 CGCAACGAGC GCAACCCCTG TCGCCAGTTG CCAGCAT-TG AG-TTGGGGA
1151 CTCTGGCGAG ACTGCTCTG -CAAGGAGCA GGAAGGCGGG GATGACGTCA
1201 AATCATCATG CCCCTTATGA CCTGGGCCAC ACACGTGCTA CAATGGACGG
1251 AGCAGAGGGA AGCGAA-GCG GCGACGCCAA GCGGATCCCA GAAACCCGTT
1301 CTCAGTTCCG ACTGCAGTCT GCAACTCGAC TGCAAGGAGC TGGAATCGCT
1351 AGTAATCGCG GATCAGCATG CCGCGGTGAA TACGTTCTCG GGCCCTGTAC
1401 ACACCGCCCG TCACACCATG AGAGTCGGCA ACACCCGAAG CCGCTGGCTC
1451 AACCCCTCGG GCAGGGAGCT GTCTAAGGTG GGGCCGATGA TTGGGGTG

```

WO 01/02008

PCT/AU00/00805

5/7

<130> 467010
 <150> PQ1376
 <151> 2 July 1999
 <210> 5
 <211> 1498
 <212> DNA
 <213> Bacteria
 <400> 5

```

1  GATGAACGCT GGC GGCGTGTC CTAATACATG CAAGTCGAAC GGGG-----
51 -ATCTTCGGA T-----TC CAGTGGCGAA CGGGTGAGGA ATACATAGGT
101 AACCTGCCCC TCCGAGGGGG ACAACAGACG GAAACATCTG -CTAAGACCG
151 CATAG-C-CA CAGGGAAGGC ATCTTCCCTG TGCCAAATGT CCTT-----T
201 CG----GGGA CAGCGGGGGC ATGGACCTAT GCGGCATTAG CTGGTTGGCG
251 GGGCAACGGC CCACCAAGGC GACGATGCGT AGCCGGCCTG AGAGGGCGGA
301 CGGCCACACT GGGACTGAGA CACGGCCCCAG ACTCCTACGG GAGGCAGCAG
351 TAGGGAATTT TCGGCAATGG GGGAAACCTT GACCGAGCAA CGCCCGCTGA
401 ACCATGAAGG CCTTCGGGTC GTAAAGTTCT GTTGC-GAAG GAAGAACGCC
451 GGTGTCAGGA AA-TGGGCGC CGGGTGACGG TACTTCGCAT AGAAAGCCAC
501 GGCTAACTAC GTGCCAGCAG CCGCGGTAAT ACGTAGGTGG CGAGCGTTAT
551 CCGGAATCAT TGGGCGTAAA GAGGGAGCAG GCGGCGATAC AGGTCTGTGG
601 TGAAATTCGG AAGCTAAACT TCGGCCAGCC AAAGAAACCG GATCGCTAGA
651 GTGCGGAAGA GGATCGTGGA ATTCCATGTG TAGCGGTGAA ATGCGTAGAT
701 ATATGGAGGA ACACCACTGG CGAAGGCGAC GGTCTGGGCC GCAACTGACG
751 CTCATTCCCC AAAGCCTGGG GAGCAAATAG GATTAGATAC CCTAGTAGTC
801 CACGCCGTAA ACCATCGATA CTAAGTGTCG GGGG----TC AA----ACCT
851 CGCTGCTGCA GTCAACGCAA TAAGTATCGC GCCTGAGTAG TACGTTCCGA
901 AGAATGAAAC TCAAAGGAAT TGACGGGGGC CCGC-ACAAG CGGTGGAGCA
951 TGTGCTTTAA TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCG
1001 ATCCAAAAGG GACGGAGACG TCCCCA---T ACCTA---TG GAGAAGACAG
1051 GTGGTGCAAT GTTGTCTGCA GCTCGTGTCT TGAGATGTTG GGTTAAGTCC
1101 CGCAACGAGC GCAACCCCTG TCGCCAGTTG CCAGCAT-TG AG-TTGGGGG
1151 CTCTGCGGAG ACTGCCTCTG -CAAGGAGGA GGAAGGCGGG GATGACGTCA
1201 AATCATCATG CCCCCTTATGA CCTGGGCCAC ACACGTGCTA CAATGGACGG
1251 AGCAGAGGGA AGCGAA-GCG GCGACGCCAA GCGGATCCCA GAAACCCGTT
1301 CTCAGTTCGG ACTGCAGTCT GCAACTCGAC TGCACGAAGC TGGGAATCGCT
1351 AGTAATCGCG GATCAGCATG CCGCGGTGAA TACGTTCTCG GGCCTTGATC
1401 ACACCCGCCG TCACACCATG AGAGTCGGCA ACACCCGAAG CCGGTGGCTC
1451 AACCCCTCGG GGAGGGAGCT GTCTAAGGTG CGGCCGATGA TTGGGGTG

```

WO 01/02008

PC1/AU00/00805

6/7

<130> 467010
 <150> PQ1376
 <151> 2 July 1999
 <210> 6
 <211> 1498
 <212> DNA
 <213> Bacteria
 <400> 6

```

1  GACGAACGCT GCGGGCGTGC TTAACACATG CAAGTCGAAC GAGGYGATT
51 WAAGCTTGCT TAGATGAGTC GAGTGGCAAA CGGGTGAGTA ACGCGTAGAC
101 AACCTGCCGC AAAGATGGGG ACAACAGTCC GAAAGGA-CT GCTAATACCG
151 AATGTTG-TC ACATTCCCCC ATGGGAGACT GATTAAAGAT GG-CCTCTAC
201 TTGTAAGCTA TCGCTTTGCG ATGGGTCTGC GTCGATTAG CTAGTTGGTG
251 GGGTAACGGC CTACCAAGGC GACGATCAGT AGCCGGTCTG AGAGGATCAA
301 CGGCCACATT GGAAGTGAGA CACGGTCCAG ACTCCTACGG GAGGCAGCAG
351 TGGGGAATCT TCCGCAATGG GCGAAAGCCT GACGGAGCAA CGCCGCGTGA
401 GTGAAGAAGG GTTTCGGCTC GTAAAGCTCT GTTGACGGG- GACGAACGTG
451 CGAGATGCGA ATAGTTTCTT GCAATGACGG TACCCGTCG- AGGAAGCCAC
501 GGCTAACTAC GTGCCAGCAG CCGCGGTAAT ACGTAGGTGG CGAGCGTTGT
551 CCGGAATTAT TGGGCGTAAA GGGAGCGCAG GCGGGAAGGC AAGTCAGTCT
601 TAAAGTGCG GGGCTCAACC CCGTGATGGG ATTGAAACTG TCTTTCTTGA
651 CTGCAGGAGA GGAAGCGGA ATTCCTAGTG TAGCGGTGAA ATGCGTAGAT
701 ATTAGGAGGA ACACCACTGG CGAAGGCGGC TTTCTGGACT GTAAC TGACG
751 CTGAGGCTCG AAGCGTGGG GAGCGAACAG GATTAGATAC CCTGGTAGTC
801 CACGCCGTAA ACGATGAATG CTAGGTGTAG GAGG--TATC GACC--CCTT
851 CTGTGCCGGA GTTAACGCAA TAAGCATTCG GCCTGGGAG TACGGTCGCA
901 AGACTGAAAC TCAAAGGAAT TGACGGGGGC CCG-CACAG CCGTGGAGTA
951 TGTGGTTTAA TTCGACGCAA CGCGAAGAAC CTTACCAGGG CTTEACATT-
1001 GAGTGAAAGG CCTAGAGATT GGTCCCTCTC TTCGGAGACA CGA-AAACAG
1051 GTGGTGCA TGCTGTCGTA GCTCGTCTCG TGAGATGTTG GGTAAAGTCC
1101 CGCAACGAGC GCAACCCCTA TCATTTGTTG CCAGCACGTC AAGGTGGGAA
1151 CTCAAATGAG ACTGCCGCGG ACAACGCGGA GGAAGGCGGG GATGACGTCA
1201 AGTCATCATG CCCCTTATGT CCTGGGCTAC ACACGTACTA CAATGGGATG
1251 GACAGAGAGC AGCGACCCCG CGAGGGCAAG CGAACCCCAT -AAACCATCT
1301 CCCAGTTCGG ATTGCAGGCT GCAACCCGCC TGCATCAAGT CGGAATCGCT
1351 AGTAATCGCT GGTCAGCATA CAGCGGTGAA TACGTTCCCG GGCCTTGATC
1401 ACACCGCCCG TCACACCACG GAAGTCATTC ACACCCGAAG CCGGTGGGTA
1451 AACCG-CA-A GGATATAGCC GTCTAAGGTG GGGGCGATGA CTGGGGTG

```

WO 01/02008

PC1/AU00/00805

7/7

<130> 467010
<150> PQ1376
<151> 2 July 1999
<210> 7
<211> 1498
<212> DNA
<213> Bacteria
<400> 7

1
51
101
151
201
251
301
351
401
451CG- AGGAAGCCAC
501 GGCTAACTAC GTGCCAGCAG CCGCGGTAAT ACCTAGGTGG CGAGCGTTGT
551 CCGGAATTAT TGGGCGTAAA GCGAGCGCAG GCGGGAAGGT AAGTCGGTCT
601 TAAAGTCCG GGGCTCAACC CCGTGATGGG ATCGAACTA TCTTTCTTGA
651 GTGCAGGACA GGAAGCGGA ATTCTTAGTG TAGCGGTGAA ATGCGTACAT
701 ATTAGGAGGA ACACCAGTGG CGAAGGCGGC TTCTGGACT GTAAGTGACC
751 CTGAGGCTCG AAAGCGTGGG GAGCGAACAG GATTAGATAC CCTGGTAGTC
801 CACGCCGTAA ACGATGAATG CTAGGTGTAG GAGG--TATC GACC--CCTT
851 CTGTGCCGGA GTTAACGCA TAAGCATTCG GCCTCGGGAG TACGGTCCGA
901 AGACTGAAAC TCAAAGGAAT TGACGGGGGC CCG-CACAAG CGGTGGAGTA
951 TGTGGTTTAA TTCGACGCA CCGCAAGAAG CTTACCAGGG CTTGACATT-
1001 GAGTGAAAGG GCTAGAGATA GCTCCCTCTC TTCGGAGACA CGA-AAACAG
1051 GTGGTGCAAT GCTGTCCTCA GCTCGTGTCTG TGAGATGTTG GGTTAAGTCC
1101 CCCAACGAGC GCAACCCCTA TCTTTTGTG CCAGCACGTC ACGGTGGCAA
1151 CTCAAAAGAG ACTGCCGCGG ACAACGCGGA GGAAGGCGGG GATCACGTCA
1201 AGTCATCATG CCCCTTATGT CCTGGGCTAC ACACGTACTA CAATGGGATG
1251 GACAGAGAGC AGCGAACCCG CGAGGGCAAG CGAACCCCAT -AAACCATCT
1301 CCCAGTTCCG ATTGCAGGCT GCAACTCGCC TGCATGAAGT CGGAATCGCT
1351 AGTAATCGCA GGTCAGCATA CTGCGGTGAA TACGTTCCCG GGCCTTGTAC
1401 ACACCGCCCG TCACACCACC CAAGTCATTG ACACCCAAAG CCGGTGGGGT
1451 AACCT-TC-G GGAGCCAGCC GTCTAAGGTG GGGGCGATGA CTGGGGTG

1/PRTS

WO 01/02008

PCT/AU00/00805

1

Control of Acidosis

Technical Field

The present invention relates to the identification of a series of microorganisms involved in the development of acidosis, together with the treatment and/or prevention and/or detection of acidosis in vertebrates, in particular, vaccines, compositions and methods for the treatment and/or prevention and/or detection of acidosis in vertebrates.

Background Art

The over production of acid in the gut of an animal by microorganisms can cause fermentative acidosis, which is defined as a condition of abnormally high acidity in the gut that can lead to local and systemic acidosis, damage to the integrity of the gut wall and increased pathogenicity of gut bacteria and parasites.

The introduction of starch, sugars or oligosaccharides into the rumen of ruminant animals and the hind gut (caecum and colon) of ruminant and non-ruminant animals including humans, leads to rapid fermentation and production of volatile fatty acids (VFA). As the rate of VFA production exceeds their rate of removal, the pH may fall below 6.0, such that lactobacilli take over, fermenting the starch to produce more lactic acid and creating an even lower pH (e.g. below 5.5). This is the scenario often presented to describe the sequential reactions in the rumen or the hind gut that lead to fermentative acidosis. The conditions of acidosis can be acute, posing an immediate life-threatening situation, or chronic (sub-acute), resulting in reductions in both feed intake and weight gain. There are also numerous disease conditions that can develop as secondary and tertiary consequences of acid accumulation in the gut.

Among the several methods for reducing the risk of acidosis, the use of antibiotic feed additives such as virginiamycin or certain ionophores have been relatively effective. However, under certain feeding conditions addition of virginiamycin has not always reduced the risk of acidosis (Godfrey *et al.*, 1995; Courtney and Seirer, 1996; Thorniley *et al.*, 1998).

Accordingly, there is a need to provide alternative means of controlling fermentative acidosis.

The main bacterial species and strains identified in the present invention, *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, have not previously been considered to be important organisms in the development of fermentative acidosis. In fact, in the case of *Selenomonas ruminantium* it should be noted that the isolate selected

by Leedle (1970) was identified on the basis of its ability to utilise lactic acid, rather than produce it, and is therefore very different to the isolates that form part of the present invention.

Therefore, the present invention has identified a series of microorganisms responsible for the development of acidosis and describes vaccines, compositions and methods for the treatment and/or prevention and/or detection of acidosis in vertebrates.

Detailed Description of the Invention

1. Vaccines/Pharmaceutical Compositions for Control of Acidosis

According to a first embodiment of the invention, there is provided a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Typically, in the vaccine of the present invention, the microorganism forms part of the normal gut flora of a vertebrate. More typically, the microorganism is involved in the aetiology of fermentative lactic acidosis in vertebrates. Still more typically, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Yet still more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4).

Yet even still more typically, the microorganism is one of the following strains deposited with the Australian Government Analytical Laboratories (AGAL) of 1 Suakin Street, Pymble, New South Wales, Australia, on 24 June 1999 and given accession numbers as outlined in the following table:

Microorganism	Accession number
<i>Streptococcus bovis</i> (SbR1 A2):	NM99/04455
<i>Streptococcus equinus</i> (SER1):	NM99/04456
<i>Streptococcus equinus</i> (SER2):	NM99/04457

WO 01/02008

PCT/AU00/00805

3

<i>Selenomonas ruminantium</i> (SRR1)	NM99/04458
<i>Selenomonas ruminantium</i> (SRR3)	NM99/04460
<i>Clostridium</i> -like <i>vitulinus</i> (LVR3)	NM99/04461
<i>Clostridium</i> -like <i>vitulinus</i> (LVR4)	NM99/04462

Alternatively, the microorganism is one of the following strains deposited with the Australian Government Analytical Laboratories (AGAL) of 1 Suakin Street, Pymble, New South Wales, Australia, on 29 June 2000 and given accession numbers as outlined in the following table:

Lab. code	Description	Accession No.
LAB 01/07-3	<i>Prevotella</i> -like, short rods arranged in short chains and filaments. Gram positive	NM00/12630
LAB 02/11-2	non-slime producing lactic acid bacterial isolate, short straight rods with round ends, also long thin rods	NM00/12631
LAB 03/D 35	<i>Prevotella</i> -like, predominantly rods in filaments. Gram+	NM00/12632
LAB 04/D37	Non-dextran slime producing <i>Streptococcus</i> isolate, predominantly large cocci, occurring mainly in pairs and singly (larger than the <i>S. bovis</i> isolates SB R1 or Sb5)	NM00/12633
LAB 05/D23	<i>Bacteroides</i> -like, predominantly small cocci < than 1 μ m in diameter mainly as diplococci: all Gram positive	NM00/12634
LAB 06/D29	Non-slime producing lactic acid bacterial isolate, long > than 5 μ m thick rods, in singles and short chains	NM00/12635
LAB 07/H1	<i>Bacteroides</i> -like, predominantly short rods forming filaments. Morphologically similar to those isolated from pigs (LAB01/07-3)	NM00/12636
LAB 08/H15	Non-slime producing lactic acid bacterial isolate, an endospore-forming bacteria, rod shaped, straight with a terminal spores. The spores are cylindrical, oval and round in shape, Gram positive	NM00/12637

Clostridium-like *vitulinus* (LVR3) and *Clostridium*-like *vitulinus* (LVR4) are new isolates. In relation to this, the 16S rRNA gene sequencing data as provided in the sequence listing (SEQ ID NOS: 1-7) of the present invention makes it clear that the organism is not a *Lactobacillus* and that it is closer to a *Clostridium*. However, it is not a

WO 01/02008

PCT/AU00/00805

4

spore-forming bacterium and cannot be classified as a member of the genus *Clostridium* *per se*. Consequently, it is necessary to name a new genus to cover the species *vitulinus*, and throughout the present specification, the organism is referred to as *Clostridium*-like *vitulinus*.

Further, the *Streptococcus bovis* (SbR1) (NM99/04455) strain of the present invention is distinct from other *Streptococcus bovis* strains, such as *Streptococcus bovis* (Sb5) (N94/8225), deposited with the Australian Government Analytical Laboratories (AGAL) of 1 Suakin Street, Pymble, New South Wales, Australia, on 8 March 1994 strain, on the basis of a number of differentiating factors. For instance, the *Streptococcus bovis* (SbR1) (NM99/04455) strain produces far less dextran exudative slime material than for example, *Streptococcus bovis* Sb5. Lack of dextran slime formation has important implications for the antigenicity and for vaccine production since the slime makes harvesting of the cells considerably more difficult. For example, in the case of *Streptococcus* isolates, dextran (slime) characteristics may be examined by centrifugation, and the absence of a bacterial "pellet" following centrifugation indicates a dextran type slime. One of the aims of the present invention was the selection for *S. bovis* bacteria that did not produce dextran slime.

Typically, the vertebrate is a monogastric, herbivore or ruminant animal or human subject. Even more typically, the vertebrate is selected from the group consisting of human, non-human primate, murine, bovine, ovine, equine, porcine, caprine, leporine, avian, feline and canine. More typically, the vertebrate is selected from the group consisting of human, ovine, camelids, porcine, bovine, equine or canine.

Typically, the vaccine comprises live or dead intact cells of at least one of the microorganisms as defined in accordance with the first embodiment of the invention. More typically, the vaccine comprises cell lysate from at least one fermentative lactic acid producing microorganisms defined in the first embodiment of the invention. Even more typically, the vaccine comprises crude antigen mixture or purified antigen or antigens from at least one fermentative lactic acid producing microorganism defined in the first embodiment of the invention. Still more typically, the vaccine comprises outer membrane and associated proteins of at least one of the microorganisms defined in the first embodiment of the invention.

Typically, the fragment or fragments of the microorganism is present in the vaccine as an immunogenic polypeptide, glycopeptide or the like.

Typically, the vaccine comprises both live or dead intact cells of at least one of the microorganisms as defined in accordance with the first embodiment of the invention.

together with outer membrane and associated proteins of at least one of these microorganisms, and/or a fragment(s) of at least one of these microorganism present as an immunogenic polypeptide, glycopeptide or the like.

Still more typically, the vaccine may be comprised of a combination of one of the following: live or dead intact cells of at least one of the microorganisms as defined in accordance with the first embodiment of the invention, outer membrane and associated proteins of at least one of these microorganisms, both dead intact cells of at least one of these microorganisms, together with outer membrane and associated proteins of at least one of the microorganisms of the invention, and/or a fragment(s) of the microorganism present as an immunogenic polypeptide, glycopeptide or the like, wherein the live or dead intact cells or outer membrane and associated proteins or immunogenic polypeptide, glycopeptide or the like, are derived from at least two microorganisms of the invention.

Typically, the vaccine is formulated for administration via intramuscular, subcutaneous, topical or other parenteral route. In general, the microorganisms of the present invention are commensal in nature, with a presence in the gut. Thus, oral administration is generally not an effective route of vaccination, and as a consequence, administration via an intramuscular, subcutaneous, topical or other parenteral route is preferred.

Typically, the vaccine may also include cytokines, such as: G-CSF, GM-CSF, interleukins or tumour necrosis factor alpha, used singly or in combination.

Typically, the vaccine may comprise a combination of two or more of the microorganisms outlined in accordance with the first embodiment of the invention.

According to a second embodiment of the invention, there is provided a pharmaceutical composition for the prevention of lactic acidosis in a vertebrate comprising at least one isolated microorganism capable of producing lactic acid within the gut of a vertebrate, or fragment or fragments thereof, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

Typically, in the pharmaceutical composition of the present invention, the microorganism forms part of the normal gut flora of a vertebrate. More typically, the microorganism is involved in the aetiology of fermentative lactic acidosis in vertebrates. Still more typically, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-

WO 01/02008

PC1...J00/00805

6

like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Yet still more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

More typically, the microorganism(s) within the pharmaceutical composition is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, the microorganism(s) within the pharmaceutical composition is provided as live cells, attenuated cells, killed whole cells, cell lysate, crude antigen mixture or purified antigen or antigens from the microorganism. More typically, the microorganism, and/or fragment or fragments thereof, is present in the pharmaceutical composition as outer membrane and associated proteins of the microorganism. Even more typically, the microorganism, and/or fragment or fragments thereof, is present as an immunogenic polypeptide or glycopeptide, or the like. Yet still more typically, the pharmaceutical composition further comprises at least one cytokine, such as: G-CSF, GM-CSF, interleukins or tumour necrosis factor alpha, used singly or in combination.

Typically, the pharmaceutical composition may comprise a combination of two or more of the microorganisms defined the second embodiment of the invention.

Typically, the microorganism present in the pharmaceutical composition may exist as a monoculture of at least one microorganism defined in the second embodiment of the

invention, or may be present as a mixed culture with other microorganisms, wherein the predominant microorganism(s) is that defined in the second embodiment of the invention.

Typically, the pharmaceutical composition in accordance with the second embodiment of the invention may also include an adjuvant. More typically, the adjuvant is selected from the group consisting of: Freund's Complete/Incomplete Adjuvant, Montenide Marcol Adjuvant, Phosphate Buffered Saline and Mannan oil emulsions, saponins (QuilA), dextran (dextran sulphate, DEAE-Dextran), aluminium compounds (Imject Alum), N-acetylglucosamyl-N-acetylmuramyl-L-alanyl-D-isoglutamine (Gerbu adjuvant). More typically, the adjuvant is selected from the group as described in the Vaccine 1995, vol 13 p 1203; 1993 vol 11 p 293; and 1992 vol 10 p 427, the disclosures of which are incorporated herein by reference.

2. Methods for Control of Acidosis

According to a third embodiment of the invention, there is provided a method for inducing an immune response against lactic acidosis in a vertebrate, said method comprising administering to said vertebrate an immunologically effective amount of the vaccine in accordance with the first embodiment of the invention, or a pharmaceutical composition in accordance with the second embodiment of the invention.

According to a fourth embodiment of the invention, there is provided the vaccine as defined in accordance with the first embodiment of the invention, or a pharmaceutical composition as defined in accordance with the second embodiment of the invention, when used in inducing an immune response against lactic acidosis in a vertebrate.

According to a fifth embodiment of the invention, there is provided the use of at least one isolated microorganism capable of producing lactic acid within the gut of a vertebrate, or fragment or fragments thereof, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, or a pharmaceutical composition as defined in accordance with the second embodiment of the invention, in the preparation of a vaccine for inducing an immune response against lactic acidosis in a vertebrate.

Still more typically, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

WO 01/02008

PCT/AU00/00805

8

Yet still more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, the vaccine or pharmaceutical composition administered in accordance with the third, fourth or fifth embodiments of the invention, may also be simultaneously or sequentially administered with cytokines, such as: G-CSF, GM-CSF, interleukins or tumour necrosis factor. Cytokines can also be combined with adjuvants to enhance the immune response.

According to a sixth embodiment of the invention, there is provided a method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of the vaccine in accordance with the first embodiment of the invention, or a pharmaceutical composition in accordance with the second embodiment of the invention.

According to a seventh embodiment of the invention, there is provided the vaccine as defined in accordance with the first embodiment of the invention, or the pharmaceutical composition as defined in accordance with the second embodiment of the invention, when used in the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis.

WO 01/02008

PCT/AU00/00805

9

According to an eighth embodiment of the invention, there is provided the use of at least one isolated microorganism capable of producing lactic acid within the gut of a vertebrate, or fragment or fragments thereof, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, in the preparation of a medicament for the treatment and/or prophylaxis of disease in a vertebrate in need of said treatment and/or prophylaxis.

Typically, the microorganism(s) used in accordance with the eighth embodiment of the invention are selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, the method in accordance with the third or sixth embodiment of the invention, the vaccine or pharmaceutical composition in accordance with the fourth or seventh embodiment of the invention, or the use in accordance with the fifth or eighth

embodiment of the invention, further comprises administering at least one cytokine, such as: G-CSF, GM-CSF, interleukins or tumour necrosis factor.

Typically, the method in accordance with the third or sixth embodiment of the invention, the vaccine or pharmaceutical composition in accordance with the fourth or seventh embodiment of the invention, or the use in accordance with the fifth or eighth embodiment of the invention, further comprises administering an active agent to the vertebrate to assist in the treatment and/or prophylaxis of lactic acidosis in the vertebrate in need of said treatment and/or prophylaxis.

Typically, in the method in accordance with the third or sixth embodiment of the invention, the vaccine or pharmaceutical composition in accordance with the fourth or seventh embodiment of the invention, or the use in accordance with the fifth or eighth embodiment of the invention, the active agent is selected from the group consisting of: antibiotics, enzyme preparations, clay preparations, compounds which slow the digesta flow, prebiotics and probiotics.

According to a ninth embodiment of the invention, there is provided a method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of an active agent capable of preventing or controlling lactic acid accumulation in the gut of a vertebrate, and wherein said lactic acid is produced by at least one microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

According to a tenth embodiment of the invention, there is provided an active agent capable of preventing or controlling lactic acid accumulation in the gut of a vertebrate, when used in the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said lactic acid is produced by at least one of the isolated microorganisms selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

According to an eleventh embodiment of the invention, there is provided use of an active agent capable of preventing or controlling lactic acid accumulation in the gut of a vertebrate, in the preparation of a medicament for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said

lactic acid is produced by at least one of the isolated microorganisms selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Typically, in the method, active agent or use in accordance with the ninth, tenth or eleventh embodiments of the invention, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, in the method, active agent or use in accordance with the ninth, tenth or eleventh embodiments of the invention, the active agent is used in conjunction with a vaccine according to the first or seventeenth embodiment of the invention.

Typically, in the method, active agent or use in accordance with the ninth, tenth or eleventh embodiments of the invention, the active agent is selected from the group consisting of: antibiotics, enzyme preparations, clay preparations, compounds which slow the digesta flow, prebiotics and probiotics.

The following relates to any one of the third through to eleventh embodiments of the invention.

Typically, the antibiotic is active against gram-positive lactic acid producing microorganisms.

Typically, the enzyme preparation is active against lactic acid producing gram-negative bacteria.

Typically, the clay preparation is active against lactic acid producing Gram-negative or Gram positive bacteria.

Typically, the compounds which slow digesta flow rate are indirectly active against lactic acid producing gram-negative bacteria. More typically, the compounds which slow digesta flow rate are typically selected from the group consisting of biologically active peptides (BAP), compounds active on the autonomic nervous system, 5HT agonists/antagonists, motilin antagonists, NO promoters, and dopamine.

Typically, the probiotic preparations include bacteria selected from the group consisting of: *Megasphaera*, *Veillenolla*, *Selenomonas*, *Propionibacterium*, *Anaerovibrio* and *Peptococcus*. More typically, the probiotic preparations include yeast and mycelial preparations capable of utilising lactic acid, and converting lactic acid to volatile fatty acids and other end products.

Typically, the active agent is active against at least one of the isolated microorganisms as defined in accordance with the first embodiment of the invention.

Typically, the antibiotic is an antibiotic active against lactic acid producing bacteria that can be selected from any listing of antibiotic compounds such as available in text books, and reports such as the Report of the Joint Expert Advisory Committee on Antibiotic Resistance (JETACAR, 1999), the disclosure of which is incorporated herein by reference.

More typically, the antibiotic is selected from the group consisting of: Acyclovir (Zovirax), Amantadine (Symmetrel), Amikacin (generic), Gentamicin (generic), Tobramycin (generic), Amoxicillin (generic), Amoxicillin/Clavulanate (Augmentin), Amphotericin B (Fungizone), Ampicillin (generic), Atovaquone (Mepron), Cefazolin (generic), Cefepime (Maxipime), Cefotaxime (Claforan), Cefuroxime (Zinacef), Chloramphenicol (generic), Clotrimazole (Mycelex), Ciprofloxacin (Cipro), Clarithromycin (Biaxin), Dicloxacillin (generic), Doxycycline (generic), Erythromycin lactobionate and other salts Fluconazole (Diflucan), Foscarnet (Foscavir), Ganciclovir (Cytovene, DHPG), Imipenem/Cilastatin (Primaxin), Ketoconazole (generic), Metronidazole (Flagyl), Nitrofurantoin, Nystatin (generic) fluconazole, or

amphotericin., Penicillin G (generic) (sodium or potassium salt), Pentamidine (generic), Piperacillin/Tazobactam (Zosyn), Rifampin (Rifadin), Ticarcillin/Clavulanate (Timentin), Trimethoprim Sulfamethoxazole, Vancomycin (generic), and any combination thereof.

More typically, the antibiotics may be used in combination with any antibiotic agents active against lactic acid producing bacteria such as *Streptococcus* spp., *Clostridium*-like and *Lactobacillus* spp. Still more typically, the antibiotic agents active against gram-positive lactic acid producing bacteria may be selected from the group consisting of: glycopeptide antibiotics, more typically, ardacin, avoparcin, teicoplanin or vancomycin; glycolipid antibiotics, more typically flavomycin (bambermycin); Streptogramin antibiotics, more typically virginiamycin; polypeptide antibiotics, more typically bacitracin zinc, bacitracin methylene disalicylate, virginiamycin S or polymyxins (B & E); macrolide antibiotics, more typically tylosin, spiramycin, virginiamycin M, josamycin, spectinomycin or erythromycin; or sulfur-containing peptide antibiotics, more typically thiopeptone, thiopeptin, sulfomycin, thiostrepton, sporangiomycin, siomycin or taitomycin; lincosamide antibiotics, more typically lincomycin or clindamycin; or pleuromutilins tiamulin; or nitrofurantoin, nitrofurazone or furazolidone; tetracycline antibiotics, more typically chlortetracycline or oxytetracycline; doxycycline, minocycline, penicillin antibiotics, more typically penicillinase-resistant penicillins, such as oxacillin or methicillin, penicillin V or ampicillin; polythiazole antibiotics, more typically nosiheptide; or ionophore antibiotics, more typically lasalocid, tetronecin, naracin or salinomycin; or, novobiocin sodium, bottromycin tartrate; streptogramin antibiotics, more typically, quinupristin/dalfopristin (RP 59500; Synercid) or streptogramin combinations [quinupristin/dalfopristin (RP 59500; Synercid)], everninomycin derivatives (SCH 27899), oxazolidinones (U-100572, U-100766); fluoroquinolone antibiotics, more typically, ciprofloxacin, ofloxacin, clinafloxacin, DU 6859a, grepafloxacin, levofloxacin, sparfloxacin or eprofloxacin, trovafloxacin; beta-lactam antibiotics; nitrovin (payzone), enramycin, mupiricin, magainin antibiotics, chloramphenicols and related compounds, including florphenicol thiamphenicol, and any combination thereof.

Typically, the antibiotics active against lactic acid producing microorganisms may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention.

Typically, the antibiotics active against gram-positive lactic acid producing microorganisms may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention. For example animals may be immunised against *Selenomonas* type bacteria and fed diets containing the antibiotic virginiamycin active against *Streptococcus* spp. and lactobacilli of lactic acid producing bacteria.

Typically, vaccines against Gram positive lactic acid producing bacteria can be used in combination with the vaccine in accordance with the first or seventeenth embodiments of the invention. For example, animals may be immunised against the Gram negative *Selenomonas* type bacteria and against *Streptococcus* spp. and *Clostridium*-like lactic acid producing bacteria.

Typically, vaccines against Gram positive lactic acid producing bacteria may also be used in combination with vaccines against Gram negative lactic acid producing bacteria, and these vaccines can also be used in conjunction with antibiotic compounds active against lactic acid bacteria.

Typically, the enzyme preparation is active against lactic acid producing gram-negative bacteria. More typically, enzyme preparations are designed to reduce the passage of fermentable carbohydrate to the hind gut through improving the digestion and absorption in the intestine of starches, disaccharides, oligosaccharides, non-starch polysaccharides, protein starch complexes and any polysaccharide which is incompletely digested in the intestine, but which is readily fermentable in the hind gut.

Typically, preferred enzymes for the break down of non-starch polysaccharides and starches include the following: glyconases including: amylase, maltase, invertase, α -glucosidases, emulsin, and amyloglucosidase; β -glucanases β -glucanase, xylanase; enzymes which break down galactosides of the raffinose series and other α -galactosides including α -galactosidase, enzymes which break down the proteins forming part of the matrix surrounding starches, sugars and non-starch carbohydrates in plant material, including: pepsin, trypsin, trypsinogen, chymotrypsin and natural and synthetic proteolytic enzymes of chemical or microbial origin, enzymes which depolymerise non-starch polysaccharides including: arabinoxylans and β -glucans, and enzymes active in the break down of cellulose, including: cellulase, enzymes active in the break down of colloidal polysaccharides, pectic substances, which include: galactouronans, galactan and arabinans, as well as the neutral polysaccharides such as xyloglucans and galactomannans and other non-starch polysaccharides such as: rhamnogalactouronan with arabinose and galactose, arabinogalactan, glucan.

xyloglucan, galactouronan with arabinose and uronan with arabinose. These enzymes can be used individually or in combination.

Typically, the enzyme preparation active against lactic acid accumulation from gram-negative lactic acid producing microorganisms may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention.

Typically, the clay preparation is active against lactic acid producing Gram-negative or Gram positive bacteria. More typically, clay preparations are designed to reduce the rate of fermentation and binds specific ions in a way which reduces the adverse effects of rapid fermentation of starch and other soluble carbohydrates in the gastrointestinal tract.

Typically, preferred clays for reducing the rate of fermentation and the osmotic effects of rapid fermentation within the gut include: kaolinite, bentonite, montmorillonite, illite, clinoptilolite, heulandite, palygorsite, saponite, smectite, chrysotile, lizardite, talc, pyrophyllite, vermiculite, beidellite, halloysite or zeolite types of clay, and these can be activated by a wide range of ions including sodium, calcium, potassium and mixtures of these and other ions. These clays can be used individually or in combination.

Typically, the clay preparation active against lactic acid accumulation from gram-negative lactic acid producing microorganisms may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention.

Typically, the compounds which slow digesta flow rate are indirectly active against lactic acid producing gram-negative bacteria. More typically, by administering compounds which slow digesta flow rate, intestinal digestion and absorption are increased, reducing the amount of fermentable substrate passing to the hind gut.

Generally, preferred agents to slow the flow of digesta include biologically active peptides (BAP) in a form which will reach the duodenum, and are active in modulating the activity of the digestive tract, gastric emptying and the rate of passage through the intestine. More typically, these biologically active peptides include opioid peptides. Compounds active on the autonomic nervous system (eg atropine and atropine-like compounds) may affect digesta flow and have similar effects. Compounds such as 5HT agonists/antagonists, motilin antagonists, NO promoters, dopamine agonists may also be used.

Whilst a range of proteins potentially produce opioid peptides on hydrolysis, the β -casomorphins, which can be derived from β -casein increasing casein during β -casein digestion, are particularly active.

Even more typically, the biologically active peptides include cholecystokinin (CCK), the M1 fraction of virginiamycin and the analogue of virginiamycin fraction M1, compound L-156. These biologically active peptides can be used individually or in combination.

It has traditionally been assumed that the nutritional benefits of proteins are only related to the essential amino acids supplied to the animal during digestion and absorption. However through the supply of biologically active peptides and the production of naturally occurring opioid peptides, the rate of digesta passage is reduced and this results in more efficient intestinal digestion and less fermentable substrate passing to the hind gut which can contribute to acidic gut syndrome.

Practical methods of supplying biologically active opioid peptides is through dietary supplementation with proteins such as casein and blood meal. For ruminant animals the best results are obtained through protection of the protein against rumen degradation by polymer coating technology, slow-release capsules, or through formaldehyde treatment.

Typically, the compounds which slow digesta rate and thereby active against lactic acid accumulation from gram-negative lactic acid producing microorganisms may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention.

Typically, probiotic agents are also active against lactic acid producing gram-negative bacteria. More typically, the probiotic reduces lactic acid accumulation from at least one of the microorganisms as defined in accordance with the first embodiment of the invention by: formation of alternative end products of fermentation; through increased utilisation of lactic acid; or through the conversion of lactic acid to volatile fatty acids which can be absorbed from the gut, thereby reducing acidity in the gut.

The effects of immunisation and antibiotic use can be further enhanced by their use in combination with probiotics in the form of bacteria selected for favourable fermentation characteristics. For example, *Megasphaera elsdenii* and certain strains of *Selenomonas ruminantium* that can ferment sugars or starch without accumulation of lactic acid may be used in a probiotic composition. Other probiotic bacteria specifically selected for reducing lactic build up during starch fermentation include Lu-12 SU109 and Sul11 (Aihua Liu, 1999 see p117). Strains of *Selenomonas ruminantium* vary significantly in their ability to ferment starch and in their ability to utilise lactic acid. While some strains have been isolated for their ability to utilise lactic acid, the strains (SRR1 and SRR3) disclosed in the present invention are aggressive producers of lactic

acid. This combination of immunisation/antibiotic treatment with the use of probiotics allows the control of lactic acid producing bacteria and thus allowing the better establishment of favourable starch utilising organisms. The effect of this combination of treatments is synergistic and not merely additive.

Typically, preferred probiotic preparations include bacteria which ferment starch and sugars to end products other than lactic acid, (ie volatile fatty acids), and bacteria which convert lactic acid to volatile fatty acids. More typically, microorganisms such as *Megasphaera elsdenii* and certain strains of *Selenomonas ruminantium* can ferment sugars or starch without accumulation of lactic acid and these strains can be used to reduce lactic acid accumulation.

More typically, the probiotic preparations may include bacteria that belong to the genera: *Succinomonas*, *Butyrivibrio*, *Bacteroides* and *Succinivibrio*. These bacteria can be used individually or in combination. More typically, the probiotic preparations may include anaerobic bacteria. Even more typically, the probiotic preparations may include bacteria selected from the group consisting of: *Megasphaera*, *Veillonella*, *Selenomonas*, *Propionibacterium*, *Anaerovibrio* and *Peptococcus*. These bacteria can be used individually or in combination. Still more typically, preferred probiotic preparations include yeast and mycelial preparations capable of utilising lactic acid, and converting lactic acid to volatile fatty acids and other end products. Yet still more typically, the probiotic preparations may include yeast and mycelial preparations such as Yea-Sacc.

Typically, at least any two of the above sample microorganisms of the probiotic preparation may be used in combination in the probiotic preparation.

Typically, the above probiotics may be used in conjunction with the vaccine in accordance with the first or seventeenth embodiments of the invention.

Typically, a combination of immunisation/active agent treatment, allows the control harmful lactic acid producing bacteria and thus allowing the better establishment of favourable starch utilising organisms. The effect of this combination of treatment is synergistic and not merely additive.

Typically, lactic acidosis is associated with a wide range of disorders, including: immune disorders, including diabetes, dermatitis, arthritis, rheumatoid arthritis, multiple sclerosis, amyotrophic lateral sclerosis, chronic fatigue syndrome, myasthenia gravis, inflammatory bowel disease, coeliac disease, irritable bowel syndrome, crohn's disease, effects on the pancreas, kidneys, thyroid and other organs of the endocrine system. and immune conditions associated with localised inflammation of sections of the gut;

homeostasis disorders, including mineral and electrolyte imbalances, such as osteoporosis; impaired reproductive performance; predisposition to ulceration of the gastrointestinal tract; respiratory tract disorders, including asthma; attention deficit disorder, autism, atopy, hypertension; infected gums and dental caries; viral infections, including herpes; predisposition to infection by bacteria, viruses and mycoplasmas fungi or protozoa; exacerbation of heat stress, and impaired hair, milk production and wool growth.

3. Nucleic acid molecules and antibodies

According to a twelfth embodiment of the invention, there is provided an isolated nucleic acid molecule comprising a polynucleotide sequence capable of selectively hybridising to at least a portion of the nucleic acid of at least one of the isolated microorganisms selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Typically, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4). *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462). *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632). *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime

producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

According to a thirteenth embodiment of the invention, there is provided an isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of: SEQ ID Nos: 1-7.

Typically, the nucleic acid molecule corresponds to a DNA or RNA molecule.

Typically, the nucleic acid molecule also includes within its scope an analogue of the polynucleotide sequence defined in accordance with the twelfth or thirteenth embodiments of the invention, wherein said analogue encodes a polypeptide having a biological activity which is functionally the same as the polypeptide(s) encoded by the polynucleotide sequence defined in accordance with the twelfth or thirteenth embodiments of the invention, wherein said polynucleotide sequence can be located and isolated using standard techniques in molecular biology, without undue trial and experimentation.

Typically, the nucleic acid molecule also includes within its scope an analogue of the polynucleotide sequence defined in accordance with the twelfth or thirteenth embodiments of the invention, which has at least 45% homology to the polynucleotide sequences so defined. More typically, the analogue of the polynucleotide sequences has at least 55% homology, still more typically the analogue has at least 60% homology, even more typically, the analogue has at least 75% homology, still more typically, the analogue has at least 85% homology, and yet still more typically, the analogue has at least 90% homology, and yet even still more typically, the analogue has at least 95-99% homology to the polynucleotide sequences so defined.

The degree of homology between two nucleic acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1996, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-453). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3.

Typically, the nucleic acid molecule also includes within its scope an analogue of the polynucleotide sequence defined in accordance with the twelfth or thirteenth embodiments of the invention, wherein said analogue is capable of hybridising to the polynucleotide sequences defined in accordance with the twelfth or thirteenth

embodiments of the invention under conditions of low stringency. More typically, low stringency hybridisation conditions correspond to hybridisation performed in conditions of low temperature and/or high salt. Even more typically, low stringency hybridisation conditions correspond to hybridisation performed at 50°C in 6xSSC.

For example, suitable experimental conditions for determining whether a given nucleic acid molecule hybridises to a specified nucleic acid may involve following the following hybridisation routine: pre-soaking of a filter containing a relevant sample of the nucleic acid to be examined in 5 x SSC for 10 min, and prehybridisation of the filter in a solution of 5 x SSC, 5 x Denhardt's solution, 0.5% SDS and 100 µg/ml of denatured sonicated salmon sperm DNA, followed by hybridisation in the same solution containing a concentration of 10 ng/ml of a ³²P-dCTP-labeled probe for 12 hours at approximately 45°C, in accordance with the hybridisation methods as described in Sambrook *et al.* (1989; Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbour, New York).

The filter is then washed twice for 30 minutes in 2 x SSC, 0.5% SDS at least 55°C (low stringency), at least 60°C (medium stringency), at least 65°C (medium/high stringency), at least 70°C (high stringency), or at least 75°C (very high stringency). Hybridisation may be detected by exposure of the filter to an X-ray film.

Further, there are many conditions and factors, well known to those skilled in the art, which may be used to alter the stringency of hybridisation. For instance, alterations to features such as: the length and nature (DNA, RNA, base composition) of the nucleic acid to be hybridised to a specified nucleic acid; concentration of salts and other components, such as the presence or absence of formamide, dextran sulfate, polyethylene glycol etc; and altering the temperature of the hybridisation and/or washing steps, all influence the dynamics and stringency of nucleic acid hybridisation.

Further, it is also possible to theoretically predict whether or not two given nucleic acid sequences will hybridise under certain specified conditions. Accordingly, as an alternative to the empirical method described above, the determination as to whether an analogous nucleic acid sequence will hybridise to the nucleic acid molecule in accordance with the twelfth or thirteenth embodiments of the invention, can be based on a theoretical calculation of the T_m (melting temperature) at which two heterologous nucleic acid sequences with known sequences will hybridise under specified conditions, such as salt concentration and temperature.

In determining the melting temperature for heterologous nucleic acid sequences ($T_m(\text{hetero})$) it is necessary first to determine the melting temperature ($T_m(\text{homo})$) for

homologous nucleic acid sequence. The melting temperature ($T_m(\text{homo})$) between two fully complementary nucleic acid strands (homoduplex formation) may be determined in accordance with the following formula, as outlined in Current Protocols in Molecular Biology, John Wilcy and Sons, 1995, as:

$$T_m(\text{homo}) = 81.5^{\circ}\text{C} + 16.6(\log M) + 0.41(\% \text{GC}) - 0.61 (\% \text{ form}) - 500/L$$

M = denotes the molarity of monovalent cations,

$\% \text{GC}$ = $\%$ guanine (G) and cytosine (C) of total number of bases in the sequence,

$\% \text{ form}$ = $\%$ formamide in the hybridisation buffer, and

L = the length of the nucleic acid sequence.

T_m determined by the above formula is the T_m of a homoduplex formation ($T_m(\text{homo})$) between two fully complementary nucleic acid sequences. In order to adapt the T_m value to that of two heterologous nucleic acid sequences, it is assumed that a 1% difference in nucleotide sequence between two heterologous sequences equals a 1°C decrease in T_m . Therefore, the $T_m(\text{hetero})$ for the heteroduplex formation is obtained through subtracting the homology % difference between the analogous sequence in question and the nucleotide probe described above from the $T_m(\text{homo})$.

Typically the nucleic acid molecule in accordance with the twelfth or thirteenth embodiments of the invention also includes within its scope a nucleic acid molecule which is an oligonucleotide fragment of these polynucleotide sequences.

Typically, the oligonucleotide fragment is between about 10 to about 100 nucleotides in length. More typically, the oligonucleotide fragment is between about 10 to about 75 nucleotides in length. Even more typically, the oligonucleotide fragment is between about 15 to about 50 nucleotides in length. Even more typically still, the oligonucleotide fragment is between about 15 to about 30 nucleotides in length. Yet still more typically, the oligonucleotide fragment is between about 5 to about 25 nucleotides in length.

According to a fourteenth embodiment of the invention, there is provided a vector comprising the nucleic acid molecule in accordance with the twelfth or thirteenth embodiments of the invention.

Typically, the vector is a shuttle or expression vector. More typically, the vector is selected from the group consisting of: viral, plasmid, bacteriophage, phagemid, cosmid, bacterial artificial chromosome, and yeast artificial chromosome. More typically, the vector is a plasmid and may be selected from the group consisting of:

WO 01/02008

PCT/AU00/00805

22

pBR322, M13mp18, pUC18 and pUC19. Even more typically, the vector is a bacteriophage and may be selected from λ gt10 and λ gt11 or phage display vectors.

According to a fifteenth embodiment of the invention, there is provided a host cell transformed with the vector in accordance with the fourteenth embodiment of the invention.

Typically, the host cells are procaryotic or eucaryotic in nature. More typically, the procaryotic host cells include bacteria, and examples of such bacteria include: *E. coli*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, and *Serratia*.

More typically, the eucaryotic host cells may be selected from the group consisting of: yeast, fungi, plant, insect cells and mammalian cells, either *in vivo* or in tissue culture. Examples of mammalian cells include: CHO cell lines, COS cell lines, HeLa cells, L cells, murine 3T3 cells, c6 glioma cells and myeloma cell lines.

According to a sixteenth embodiment of the invention, there is provided an antibody raised against at least one lactic acid producing microorganism, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Typically, the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like

virulinus (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, the antibody in accordance with the sixteenth embodiment of the invention is raised against at least one of the following:

- (a) at least one fermentative lactic acid producing microorganism as defined in the sixteenth embodiment of the invention;
- (b) intact cells of least one fermentative lactic acid producing microorganism as defined in the sixteenth embodiment of the invention;
- (c) cell lysate from at least one fermentative lactic acid producing microorganism as defined in the sixteenth embodiment of the invention;
- (d) crude antigen mixture or purified antigen or antigens from at least one fermentative lactic acid producing microorganism as defined in the sixteenth embodiment of the invention;
- (e) outer membrane and associated proteins of at least one fermentative lactic acid producing microorganism as defined in the sixteenth embodiment of the invention.

Typically, the antibodies in accordance with the sixteenth embodiment may be present in a composition further comprising antibodies raised against at least one of the following:

- (f) at least one fermentative lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli;
- (g) intact cells of at least one fermentative lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli;
- (h) cell lysate from at least one fermentative lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli;
- (i) crude antigen mixture or purified antigen or antigens from at least one fermentative lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli;
- (j) outer membrane and associated proteins of at least one fermentative lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli.

WO 01/02008

PC. J00/00805

24

More typically, the antibodies in accordance with the sixteenth embodiment may be present in a composition further comprising antibodies raised against at least one of the following:

(k) *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255;

(l) intact cells of *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255;

(m) cell lysate from *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255;

(n) crude antigen mixture or purified antigen or antigens from *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255;

(o) outer membrane and associated proteins of *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

Typically, the antibodies in accordance with the sixteenth embodiment of the invention can be comprised of a polyclonal mixture, or may be monoclonal in nature. Further, antibodies can be entire immunoglobulins derived from natural sources, or from recombinant sources. The antibodies of the present invention may exist in a variety of forms, including for example as a whole antibody, or as an antibody fragment, or other immunologically active fragment thereof, such as complementarity determining regions.

The antibody (or fragment thereof) in accordance with the sixteenth embodiment of the present invention has binding affinity to a microorganisms capable of producing acid in the gut of vertebrates in vertebrates. Preferably, the antibody (or fragment thereof) has binding affinity or avidity greater than about 10^5 M^{-1} , more preferably greater than about 10^6 M^{-1} , more preferably still greater than about 10^7 M^{-1} and most preferably greater than about 10^8 M^{-1} .

The techniques for generating and reviewing binding affinity are reviewed in Scatchard (1949), Annals of the New York Academy of Sciences, 51, 660-672, and Munson (1983), Methods in Enzymology 92, 543-577, the contents of each of which are incorporated herein by reference.

WO 01/02008

PCT/AJ00/00805

25

According to a seventeenth embodiment of the invention, there is provided a vaccine comprising at least one of the antibodies in accordance with the sixteenth embodiment of the invention, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

4. Diagnosis of Acidosis

According to an eighteenth embodiment of the invention, there is provided a diagnostic kit for the detection of microorganisms having a role in lactic acidosis in a vertebrate, said kit comprising at least one of the antibodies in accordance with the sixteenth embodiment of the invention, together with a diagnostically acceptable carrier and/or diluent.

Typically, the diagnostic kit may also contain antibodies capable of detecting at least one lactic acid producing strain selected from : *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Typically, the kits will also include analytical methods to measure the extent of lactic acid production, specifically lactic acid in order to determine functional aspects of the lactic acid producing bacteria. More typically, the kit also contains reagents for measuring acidity and capacity to produce lactic acid as well as the detection of the microorganisms responsible for the lactic acid production. The kit may contain reagents and equipment to measure pH of digesta or faecal material and fermentation tubes for measuring the potential lactic acid production with added carbohydrate. Both pH and lactic acid are typically detected using colour or other visual changes, spectrophotometric methods or through instruments such as pH meters.

More typically, the diagnostic kit may also contain antibodies capable of detecting microorganisms selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

Even more typically, the diagnostic kit may also contain antibodies capable of detecting microorganisms selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-

WO 01/02008

PCT/AU00/00805

26

slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3), *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05. *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) are selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460), *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637), together with *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

Typically, the kit may comprise the following containers:

(a) a first container containing at least the antibody (or fragment thereof) in accordance with the sixteenth embodiment of the invention, and;

(b) a second container containing a conjugate comprising a binding partner of the antibody (or fragment thereof), together with a detectable label.

More typically, the first container containing at least the antibody (or fragment thereof) in accordance with the sixteenth embodiment of the invention, may further comprise antibodies selected from the group consisting of: antibodies capable of detecting at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli and antibodies capable of detecting *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

More typically, the kit may further comprise one or more other containers, containing other components, such as wash reagents, and other reagents capable of

detecting the presence of bound antibodies. Even more typically, the detection reagents may include: labelled (secondary) antibodies, or where the antibody (or fragment thereof) in accordance with the sixteenth embodiment of the invention is itself labelled, the compartments may comprise antibody binding reagents capable of reacting with the labelled antibody (or fragment thereof) of the present invention.

According to a nineteenth embodiment of the invention, there is provided a method for screening for the presence of microorganisms having a role in acidosis in a vertebrate, said method comprising:

- (a) contacting a sample from the gut of a vertebrate with the antibody (or fragment thereof) in accordance with the sixteenth embodiment of the invention, and
- (b) detecting the presence of the antibody (or fragment thereof) bound to microorganisms having a role in acidosis.

Typically, the antibody used in the method in accordance with the nineteenth embodiment of the invention corresponds to an antibody mix, comprising antibody or fragment thereof in accordance with the sixteenth embodiment of the invention, together with an antibody(s) selected from the group consisting of: antibodies capable of detecting at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli and antibodies capable of detecting *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

According to a twentieth embodiment of the invention, there is provided a method for screening for the presence of microorganisms having a role in acidosis in a vertebrate, said method comprising contacting a nucleic acid sample from a microorganism with a nucleic acid probe, wherein the microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, isolated from the gut of a vertebrate, and

- (b) detecting hybridisation between the nucleic acid sample and the polynucleotide sequence.

Typically, the microorganism is selected from the group consisting of: microorganisms selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more

WO 01/02008

28

typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1); *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05. *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, hybridisation as compared to non-hybridisation is indicative of the presence of microorganisms having a role in acidosis.

Typically, the nucleic acid probe corresponds to a portion of the polynucleotide sequence in accordance with the twelfth or thirteenth embodiments of the invention which is capable of selectively hybridising to nucleic acid from a sample of gut microorganisms as defined in the first embodiment of the invention. More typically, the nucleic acid probe corresponds to a probe mix, comprising a portion of the polynucleotide sequence in accordance with the twelfth or thirteenth embodiments of the invention which is capable of selectively hybridising to nucleic acid from a sample, together with an isolated nucleic acid molecule comprising a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli, or a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of the microorganism strain *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

Typically, hybridisation may occur and be detected through techniques that are routine and standard amongst those skilled in the art, and include southern and northern hybridisation, polymerase chain reaction (PCR) and ligase chain reaction (LCR) amplification.

Various low or high stringency hybridisation levels may be used, depending on the specificity and selectivity desired.

Typically, the microorganisms detected in accordance with the nineteenth or twentieth embodiment of the invention may also include lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli. More typically, the microorganisms detected in accordance with the nineteenth or twentieth embodiment of the invention may include *Streptococcus bovis* (strain Sb-5) deposited with the Australian Government Analytical Laboratories (AGAL) on 8 March 1994, and given accession number N94/8255.

According to a twenty-first embodiment of the invention, there is provided a method for screening for potential therapeutic agents for the treatment of lactic acidosis in a vertebrate, said method comprising

- (a) contacting the potential therapeutic agent with a microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, and
- (b) detecting an effect of the potential therapeutic agent on said microorganism.

Typically, the microorganism is selected from the group consisting of: microorganisms selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08. Even more typically, the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1), *Streptococcus equinus* (SER1); *Streptococcus equinus* (SER2); *Selenomonas ruminantium* (SRR1); *Selenomonas ruminantium* (SRR3); *Clostridium*-like *vitulinus* (LVR3); *Clostridium*-like *vitulinus* (LVR4), *Prevotella*-like isolates LAB01 and LAB03, *Bacteroides*-like isolates LAB07, *Enterococcus*-like isolate LAB05, *Streptococcus bovis* SbR1, non-dextran slime producing *Streptococcus* isolate LAB04 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

WO 01/02008

PC...U00/00805

30

Yet still more typically, the microorganism(s) is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Typically, the screening method determines whether the potential therapeutic agent has a role in a lactic acid production pathway in at least one of the microorganisms of the invention. For example, the screening method in accordance with the twenty-first embodiment of the invention may identify a therapeutic agent which affects a critical step in the lactic acid biosynthetic pathway, such as blocking the conversion of pyruvate to lactate by inactivating the enzyme lactate dehydrogenase, or blocking the conversion of malate to lactate by inactivating malolactic enzyme.

According to a twenty-second embodiment of the invention, there is provided an isolated culture of at least one microorganism selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455); *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462); *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632); *Bacteroides*-like isolate LAB07 (NM00/12636); *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1); non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633); and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

Definitions

The term "antibody" means an immunoglobulin molecule able to bind to a specific epitope on an antigen. Antibodies can be comprised of a polyclonal mixture, or may be monoclonal in nature. Further, antibodies can be entire immunoglobulins derived from natural sources, or from recombinant sources. The antibodies of the present invention may exist in a variety of forms, including for example as a whole antibody, or as an antibody fragment, or other immunologically active fragment thereof, such as complementarity determining regions. Similarly, the antibody may exist as an antibody fragment having functional antigen-binding domains, that is, heavy and light chain variable domains. Also, the antibody fragment may exist in a form selected from the group consisting of: Fv, Fab, F(ab)₂, scFv (single chain Fv), dAb (single domain antibody), bi-specific antibodies, diabodies and triabodies.

The term "isolated" means that the material in question has been removed from its host, and associated impurities reduced or eliminated. Essentially, it means an object species is the predominant species present (ie., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 30 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 to 90 percent of all macromolecular species present in the composition. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

As used herein the term "polypeptide" means a polymer made up of amino acids linked together by peptide bonds.

In the context of this specification, the term "comprising" means "including principally, but not necessarily solely". Further, variations of the word "comprising", such as "comprise" and "comprises" have correspondingly varied meanings.

Brief Description of the Drawings

Figure 1 describes a phylogenetic tree illustrating the phylogenetic relationship of the bacterial species and strains of the present invention.

Best Mode of Performing the Invention

1. Isolation of Microorganisms involved in acidosis

The following method provides a means of isolating microorganisms involved in acidosis. Fluid samples are taken from caecal, colonic, rectal or faecal material from

WO 01/02008

PCT/AU000805

32

animals or humans consuming a diet containing more than half of the dry matter as sugars, oligosaccharides or starch. This material (one part) may then be mixed well with distilled water (9 parts), prior to straining through 4 layers of cheese cloth and serially diluting in ten-fold steps using anaerobic dilution solution (ADS) (Caldwell and Bryant, 1966) to a final dilution of 10^{-8} .

The material so diluted (10^{-6} , 10^{-7} and 10^{-8}) is then used to inoculate media roll tubes prepared with modified semi-selective MRS-Agar medium, Oxoid, England (de Man *et al.*, 1960), together with adjustment of the pH of the medium to 5.5. Three replicate tubes are used for each dilution and they are incubated at 39°C for three days.

The colonies so prepared are then carefully studied under a low power (x4) microscope to identify the most common colonies based on physical appearance and growth characteristics. These colonies are then enumerated at the three dilutions (10^{-6} , 10^{-7} and 10^{-8}) to confirm a consistent representation. At this stage, samples are taken of at least five colonies that have been counted as being of the same most common characteristics to confirm similarity, and are examined under high power magnification ($>40\times$) using gram staining to determine that the cells are similar.

Once this is done, viable colonies representing the dominant colony type are picked and used to inoculate a broth of basal medium 10 containing glucose (0.5%). This process of inoculation is repeated into MRS roll tubes and again examined for uniformity among colonies. At this stage, at least three examples of the most common colonies are examined and if these appear identical, representative colonies are picked and used to inoculate a broth of BM10. The process of roll tube and broth cultures is repeated until it is clear that a purified isolate has been obtained. In some cases, it is possible that two or more bacteria are very closely associated and in this case a crude isolate is maintained as the antigenic unit.

In the case of *Streptococcus* isolates, dextran (slime) characteristics are examined by centrifugation at 17,000g for 15 minutes. The absence of a bacterial "pellet" following centrifugation indicates a dextran type slime. One of the aims of the present invention was the selection for *S. bovis* bacteria that did not produce dextran slime.

Finally, characteristics of the isolate can then be determined by measuring the range of substrate utilisation and rate of lactic acid production.

2. Vaccine/Pharmaceutical Compositions and Methods for Control of Acidosis

In a process of preparing a vertebrate vaccine of the invention, a typical protocol includes: washing the microbial growth free of nutrient medium, killing, harvesting and

WO 01/02008

PCT/AU00/00805

33

suspension of the dead cells of the microorganisms in a pharmaceutically/veterinarily acceptable carrier, diluent, excipient and/or adjuvant.

An alternative typical protocol includes: washing the microbial growth free of nutrient medium, rupturing to form outer membrane and associated proteins, separating whole cells from outer membrane and associated proteins, suspension of the outer membrane and associated proteins in a pharmaceutically/veterinarily acceptable carrier, diluent, excipient and/or adjuvant.

In delivery systems utilising the parenteral route it is preferred that dead cells of the microorganisms and/or outer membrane and associated proteins, are suitably washed, harvested and resuspended in a pharmaceutically/veterinarily acceptable carrier, diluent and/or adjuvant suitable for injection, utilising methods of administration as are well known in the art.

In the administration of therapeutic formulations in accordance with the present invention and herein disclosed, there are preferred non-toxic pharmaceutical carriers, diluents, excipients and/or adjuvants. For administration of the above formulations the microorganism or fragment or fragments thereof of the present invention are admixed with these non-toxic carriers, diluents, excipients and/or adjuvants and may be in the form of capsules, aqueous or oily suspensions, emulsions, micelles or injectable solutions.

Examples of pharmaceutically and veterinarily acceptable carriers or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysiloxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-butyleneglycol or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinylpyrrolidone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 10% to 99.9% by weight of the compositions.

Adjuvants typically include emollients, emulsifiers, thickening agents, preservatives, bactericides, cytokines and buffering agents.

In general to induce the production of antibodies to the vaccines of the invention, they can be oleogenous or aqueous suspensions formulated in accordance with known methods in the art using suitable dispersing, suspension and/or wetting agents. Examples of suitable dispersing, suspension and wetting agents include Freund's complete/incomplete adjuvant, Montenide Marcol adjuvant and phosphate buffered saline, and mannan.

It will be appreciated that the examples referred to above are illustrative only and other suitable carriers, diluents, excipients and adjuvants known to the art may be employed without departing from the spirit of the invention.

For administration as an injectable solution or suspension, non-toxic parenterally acceptable diluents or carriers can include Ringer's solution, isotonic saline, phosphate buffered saline, ethanol and 1,2 propylene glycol.

Further, a vaccine composition containing a recombinant polypeptide as encoded by at least one of the nucleic acid molecules in accordance with the twelfth or thirteenth embodiment of the invention, may be prepared for use by standard methods, well known to those of ordinary skill in the art.

In one embodiment, the immunogenic polypeptide, glycopeptide or the like, may be produced in a recombinant system by expression of the polynucleotide sequence (or a fragment thereof) in accordance with the twelfth or thirteenth embodiments of the invention, and subsequently isolated. For example, microbial cells containing the nucleic acid molecule of interest may be cultured in large volume bioreactors, then collected by centrifugation and subsequently ruptured, for instance by high-pressure homogenisation. The resulting cell lysate may be resuspended in appropriate diluent such as those described herein, and filtered to obtain an aqueous suspension of the immunogen. The recombinant protein can be administered in crude form, for example, by diluting in a 0.1M phosphate buffer (pH 7.4) to 50-500 µg/ml concentration, and then passing through a sterile 0.22 micron filter.

Alternatively, a vaccine composition containing the recombinant immunogenic polypeptide, glycopeptide or the like, may be prepared in a mammalian expression system, utilising host cells such as Chinese Hamster Ovary (CHO) cells. The recombinant polypeptide, glycopeptide or the like, (or fragment thereof) may be manufactured using batch fermentation with serum free medium. After fermentation the recombinant polypeptide, glycopeptide or the like, (or fragment thereof) may be

purified via a multistep procedure incorporating chromatography and viral inactivation/removal steps. For instance, the recombinant polypeptide, glycopeptide or the like, (or fragment thereof) may be first separated by Protein A affinity chromatography and then treated with solvent/detergent to inactivate any lipid enveloped viruses. Further purification, typically by anion and cation exchange chromatography may be used to remove residual proteins, solvents/detergents and nucleic acids. The purified recombinant polypeptide, glycopeptide or the like, (or fragment thereof) may be further purified and formulated into 0.9% saline using gel filtration columns. The formulated bulk preparation may then be sterilised and viral filtered and dispensed.

Alternatively, a vaccine composition containing an immunogenic polypeptide, glycopeptide or the like, of the microorganism of the present invention may be prepared by synthesis of a peptide, using standard methods known to those in the art, such as by automated synthesis on, for instance, an Applied Biosystems model 430A. For example, the peptide may comprise selected amino acid regions of the CDR and/or FR of the polypeptide of the invention. The synthetic peptide can be administered, for example, after diluting in a 0.1M phosphate buffer (pH 7.4) to 50-500 µg/ml concentration, and passing through a sterile 0.22 micron filter.

Alternatively, the vaccine may be a DNA based vaccine. In one aspect, the DNA based vaccine may comprise naked DNA comprising a nucleic acid encoding an immunogenic polypeptide of the microorganism of the present invention, or a fragment thereof.

In another aspect, the DNA based vaccine may comprise a nucleic acid molecule encoding an immunogenic polypeptide of the microorganism of the present invention, or a fragment thereof, cloned into an expression vector. Typically, the expression vector is a eucaryotic expression vector and may include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.

A typical vaccination regime is to deliver the vaccine in multiple doses generally one, two or three equal doses.

The vaccines of the invention are typically formulated for administration by parenteral route, by inhalation or topically. The term parenteral as used herein includes intravenous, intradermal, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal

administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred.

A vaccine or pharmaceutical composition of the invention may also be administered topically, such as externally to the epidermis, to the buccal cavity and instillation of such an antibody into the ear, eye and nose.

The amount of the vaccine or pharmaceutical composition of the invention required for therapeutic or prophylactic effect will, of course, vary with the vaccine or pharmaceutical composition chosen, the nature and severity of the condition being treated and the animal undergoing treatment, and is ultimately at the discretion of the physician or veterinarian. A suitable topical dose of a vaccine or pharmaceutical composition of the invention will generally be within the range of about 1 to about 100 milligrams per kilogram body weight daily; preferably about 0.05 to about 50, more preferably about 0.5 to about 25, even more preferably about 0.5 to about 10 milligrams per kilogram body weight per day.

The parenteral dosage regimens for employing compounds of the invention to prophylactically or therapeutically control lactic acidosis will generally be in the range of about 0.01 to about 100, preferably about 0.01 to about 50, more preferably about 0.05 to about 25, even more preferably about 0.1 to about 2 milligrams per kilogram body weight per day. Alternatively, dosage rates can be determined in relation to metabolic rate or surface area of the body.

A vaccine or pharmaceutical composition of the invention may also be administered by inhalation, that is, intranasal and/or inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The preferred dosage amount of a compound of the invention to be employed is generally within the range of about 0.05 to about 100, preferably about 0.05 to about 50, more preferably about 0.5 to about 25, even more preferably about 0.5 to about 10 milligrams per kilogram body weight per day.

Typically, the dosage rate for immunisation is between 1×10^6 and 1×10^{11} bacterial cells per administration.

Typically, the dosage rates are approximately equivalent to between 1×10^8 to 1×10^9 bacterial cells per kg body weight. More typically, the dosage rates are approximately equivalent to between 1×10^8 and 5×10^8 bacterial cells per kg body weight. Even more typically, the dosage rates are approximately equivalent to 2.5×10^8 bacterial cells per kg body weight.

Typically, the dosage rate for immunisation of small animals, such as sheep, is between 1×10^9 and 5×10^{10} bacterial cells per injection. More typically, the dosage rate for immunisation of small animals, such as sheep, is approximately 5×10^9 bacterial cells per administration.

Typically, the dosage rate for immunisation of large animals, such as cattle and horses, is between 1×10^9 and 1×10^{12} bacterial cells per injection. More typically, the dosage rate for immunisation of large animals, such as cattle and horses, is approximately 1×10^{10} bacterial cells per administration.

Typically, the injection volume for sheep is between 1 mL to 3 mL, and 2 to 7 mL for cattle and horses 3 to 5 mL. More typically, the injection volume for sheep is between 1 mL to 2 mL, and 1 to 5 mL for cattle and horses.

In accordance with any one of the third through to eleventh embodiments of the invention, the administered dose of the antibiotic can vary and will depend on several factors, such as the condition, age and size of the human or animal patient, as well as the nature of the lactic acid producing bacteria.

Dosages will typically range from between any one of the following: 0.01 and 100 mg per kg of bodyweight; 0.01 and 75 mg per kg of bodyweight; 0.01 and 50 mg per kg of bodyweight; 0.01 and 25 mg per kg of bodyweight; 0.01 and 15 mg per kg of bodyweight; 0.01 and 10 mg per kg of bodyweight; and 0.01 and 5 mg per kg of bodyweight. More typically dosages will range from between 0.02 and 2.0 mg per kg of bodyweight. More typically dosages will range from between 0.05 and 1.0 mg per kg of bodyweight. Even more typically dosages will range from between 0.1 and 0.5 mg per kg of bodyweight. Yet even more typically, the antibiotic is administered to the human or animal at a rate of 0.4 mg per kg of bodyweight.

Typically, the antibiotic is administered at a rate of between 1 and 100 mg per kg of dry weight of food. More typically, the antibiotic is administered at a rate of between 1 and 75 mg per kg of dry weight of food. Even more typically, the antibiotic is administered at a rate of between 1 and 50 mg per kg of dry weight of food. Yet even more typically, the antibiotic is administered at a rate of between 5 and 40 mg per kg of dry weight of food.

Typically, antibiotic preparations are selected and/or formulated for delivery to the hind gut and for little or no absorption from the digestive tract. Formulations include encapsulation and/or coating with materials resistant to acid and enzymic digestion in the stomach and small intestine. Formulation can also include chemical treatment to reduce the solubility of the antibiotic.

WO 01/02008

PC1...J00/00805

38

As above, the administered dose of the enzyme preparation can vary and will depend on several factors, such as the condition, age and size of the human or animal patient, as well as the nature of the carbohydrate. Dosages will typically range from between 0.01 and 50 g/kg food dry matter. Typically, the enzyme is administered at a rate of between 0.1 and 3 g per kg of dry weight of food. More typically, the enzyme is administered at a rate of between 1 g per kg of dry weight of food.

Similarly, the administered dose of the clay preparation can vary and will depend on several factors, such as the condition, age and size of the human or animal patient, as well as the nature of the carbohydrate. Dosages will typically range from between 0.5 and 100 g/kg food dry matter. Typically, the clay is administered at a rate of between 1 and 50 g per kg of dry weight of food. More typically, the clay is administered at a rate of between 10 and 20 g per kg of dry weight of food.

Typically, the administered dose of the probiotic preparation can vary between 10^4 and 10^{12} bacteria per kg of body weight. More typically, dose of the probiotic preparation can vary between 10^4 and 10^{10} per kg of body weight. Even more typically, dose of the probiotic preparation can vary between 10^4 and 10^6 per kg of body weight.

Typically, probiotics are formulated in such a way as to deliver viable bacteria and/or other microorganisms to gastrointestinal tract including the hind gut. These formulation techniques include coatings and encapsulation using materials resistant to gastric and intestinal digestion.

According to another form of the invention, the active agents can be used together.

According to another aspect of the invention, the formulation of the active agent ensures that it is administered in a palatable form to the animal or human and in a form which retains activity and is properly mixed in the appropriate compartment(s) of the gastrointestinal tract.

Generally, the active agent is administered regularly throughout the period the animal or human is subjected to a high carbohydrate diet or to sugars or other fermentable compounds which are not efficiently absorbed prior or reaching the large intestine, colon and caecum.

More typically, the active agent is administered 1-3 times daily. Even more typically, the active agent is administered once daily or can be included in human food and animal feeds. They can be fed as powders or suspended in water, included in pellets as well as being fed in premixes.

More typically the active agent is mixed with the food, or is added to feeds which contain starch or sugars which may produce an acidic pattern of fermentation in the gastrointestinal tract. The active agent can also be added to water included in tablets and the like.

5 A suitable treatment may include the administration of a single dose or multiple doses. Usually, the treatment will consist of administering one dose daily of the active agent for a period sufficient to control the accumulation of acid by fermentation of the carbohydrate in the gastrointestinal tract. Dosing may continue while sources of carbohydrate known to cause problems of acidic fermentation in the gastrointestinal tract are included in the diet.

More typically the active agent may be administered in a single dose immediately before consuming meals containing sources of carbohydrate which are poorly digested and rapidly fermented.

15 More typically, the active agent is administered for one day prior to and daily during the consumption of excessive quantities of food stuffs containing readily fermentable carbohydrates.

Typically, the active agent is administered orally.

3. Antibodies

20 Antibodies or immunoglobulins are typically composed of four covalently bound peptide chains. For example, an IgG antibody has two light chains and two heavy chains. Each light chain is covalently bound to a heavy chain. In turn each heavy chain is covalently linked to the other to form a "Y" configuration, also known as an immunoglobulin conformation. Fragments of these molecules, or even heavy or light chains alone, may bind antigen.

25 A normal antibody heavy or light chain has an N-terminal (NH_2) variable (V) region, and a C-terminal (COOH) constant (C) region. The heavy chain variable region is referred to as V_H (including, for example, V_γ), and the light chain variable region is referred to as V_L (including V_κ or V_λ). The variable region is the part of the molecule that binds to the antibody's cognate antigen, while the F_c region (the second and third domains of the C region) on the heavy chain determines the antibody's effector function (eg. complement fixation, opsonization). Full-length immunoglobulin or antibody "light chains" are encoded by a variable region gene at the N-terminus and a κ (kappa) or λ (lambda) constant region gene at the COOH -terminus. Full-length immunoglobulin or antibody "heavy chains", are similarly encoded by a variable region gene and one of the constant region genes, eg., gamma. Typically, the " V_L " will include the portion of the

WO 01/02008

PCI. 30/06002

40

light chain encoded by the V_L and J_L (J or joining region) gene segments and the " V_H " will include the portion of the heavy chain encoded by the V_H , and D_H (D or diversity region) and J_H gene segments.

An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, also called complementarity-determining regions or CDRs. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus.

The two types of light chains, κ (kappa) and λ (lambda), are referred to as isotypes. Isotypic determinants typically reside in the constant region of the light chain, also referred to as the C_L in general, and C_κ or C_λ in particular. Likewise, the constant region of the heavy chain molecule, also known as C_H , determines the isotype of the antibody. Antibodies are referred to as IgM, IgD, IgG, IgA, and IgE depending on the heavy chain isotype. The isotypes are encoded in the μ (mu), δ (delta), γ (gamma), α (alpha), and ϵ (epsilon) segments of the heavy chain constant region, respectively.

The heavy chain isotypes determine different effector functions of the antibody, such as opsonisation or complement fixation. In addition, the heavy chain isotype determines the secreted form of the antibody. Secreted IgG, IgD, and IgE isotypes are typically found in single unit or monomeric form. Secreted IgM isotype is found in pentameric form; secreted IgA can be found in both monomeric and dimeric form.

In a related aspect, the invention features a monoclonal antibody, or an Fab, (Fab)₂, scFv (single chain Fv), dAb (single domain antibody), bi-specific antibodies, diabodies and triabodies, or other immunologically active fragment thereof (eg., a CDR-region). Such fragments are useful as immunosuppressive agents. Alternatively, the antibody of the invention may have attached to it an effector or reporter molecule. For instance, an antibody or fragment thereof of the invention may have a macrocycle, for chelating a heavy metal atom, or a toxin, such as ricin, attached to it by a covalent bridging structure. In addition, the Fc fragment or CH₃ domain of a complete antibody molecule may be replaced or conjugated by an enzyme or toxin molecule, such as chelates, toxins, drugs or prodrugs, and a part of the immunoglobulin chain may be bonded with a polypeptide effector or reporter molecule, such as biotin, fluorochromes,

phosphatases and peroxidases. Bispecific antibodies may also be produced in accordance with standard procedures well known to those skilled in the art.

The present invention further contemplates genetically modifying the antibody variable and/or constant regions to include effectively homologous variable and constant region amino acid sequences. Generally, changes in the variable region will be made to improve or otherwise modify antigen binding properties of the antibody or fragment thereof. Changes in the constant region will, in general, be made in order to improve or otherwise modify biological properties, such as complement fixation, interaction with membranes, and other effector functions.

Typically, the antibodies in accordance with the sixteenth embodiment of the invention can be comprised of a polyclonal mixture, or may be monoclonal in nature. Further, antibodies can be entire immunoglobulins derived from natural sources, or from recombinant sources. The antibodies of the present invention may exist in a variety of forms, including for example as a whole antibody, or as an antibody fragment, or other immunologically active fragment thereof, such as complementarity determining regions.

Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. For example, spleen cells from an animal immunised with a desired antigen are immortalised, commonly by fusion with a myeloma cell, in a manner as described for example, in Kohler and Milstein, Eur. J. Immunol., 6:511-519 (1976), the disclosure of which is incorporated herein by reference.

Alternative methods of immortalisation include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalised cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Various techniques useful in these arts are discussed, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor, New York (1988), the disclosure of which is incorporated herein by reference, including: immunisation of animals to produce immunoglobulins; production of monoclonal antibodies; labelling immunoglobulins for use as probes; immunoaffinity purification; and immunoassays.

4. An antibody/nucleic acid based method and kit for detecting acidosis activity

The present invention also encompasses a method of detecting in a sample the presence of microorganisms involved in lactic acidosis and/or the potential acid producing characteristics of the microorganisms, wherein the method comprises:

(a) contacting a sample with the antibody (or fragment thereof) as defined in accordance with the sixteenth embodiment of the invention. and

(b) detecting the presence of the antibody (or fragment thereof) bound to a microorganism or (fragment thereof) involved in lactic acidosis.

Typically, the method of detecting in a sample the presence of microorganisms involved in lactic acidosis, or potential lactic acid producing microorganisms may also comprise:

(c) measuring lactic acid present in the digesta or faecal sample or measuring pH of said sample; or

(d) measuring amount of lactic acid produced when microorganisms ferment carbohydrate.

Conditions for incubating an antibody (or fragment thereof) with a test sample vary widely, depending on the format of detection used in the assay, the detection method, and the type and nature of the antibody used. A person of ordinary skill in the art would readily appreciate that any one of the commonly available immunological assays could be used in performing the method of detection. For example, these assays include: radioimmunoassays, enzyme-linked immunosorbent assays, and/or immunofluorescent assays.

A kit for performing the above method of the invention contains all the necessary reagents to carry out the above methods of detection. For example, the kit may comprise the following containers:

(a) a first container containing the antibody (or fragment thereof) in accordance with the sixteenth embodiment of the present invention;

(b) a second container containing a conjugate comprising a binding partner of the antibody (or fragment thereof), together with a detectable label.

Typically, the kit may further comprise one or more other containers, containing other components, such as wash reagents, and other reagents capable of detecting the presence of bound antibodies. More typically, the detection reagents may include: labelled (secondary) antibodies, or where the antibody (or fragment thereof) of the present invention is itself labelled, the compartments may comprise antibody binding reagents capable of reacting with the labelled antibody (or fragment thereof) of the present invention.

Further, the kit of the present invention, as described above in relation to antibodies, can be readily incorporated, without the expenditure of inventive ingenuity, into a kit for nucleic acid probes. One skilled in the art would select the nucleic acid probe from the polynucleotides of the present invention, according to techniques known in the art as described above. Samples to be tested include but should not be limited to RNA samples of vertebrate tissue.

Such a kit comprises at least one container means having disposed therein the above-described nucleic acid probe. The kit may further comprise other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe. Examples of detection reagents include, but are not limited to radiolabelled probes, enzymatic labelled probes (horseradish peroxidase, alkaline phosphatase), and affinity labelled probes (biotin, avidin, or streptavidin).

In detail, a compartmentalised kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and like), and containers which contain the reagent detect the hybridised probe, bound antibody, amide product, or the like.

Furthermore, one skilled in the art would readily recognise that the nucleic acid probes in the present invention can readily be incorporated into one of the established kit formats, which are known in the art.

In terms of measuring lactic acid production, the pH of digesta or faecal material can be measured using colour sensitive reagents or a pH meter. Lactic acid can be detected using colorimetric techniques using enzymes, colour reagents and assays assessed with the naked eye or using spectrometric techniques. Further, identifying potential lactic acid producing bacteria involves incubation of the sample with carbohydrate followed by measurement of lactic acid, pH and lactic acid producing bacteria.

The invention will now be described in greater detail by reference to specific Examples, which should not be construed as in any way limiting on the scope thereof.

WO 01/02008

PCT/AU00/00805

44

Examples

Example 1

Control of *S. ruminantium*, *Clostridium*-like *vitulinus*, *S. bovis* and *S. equinus*.

Materials and Methods

Isolation, Identification and characterisation of lactic acid producing bacteria

The following method was used to isolate the most numerous and most prolific acid-producing bacteria in the gut contents of ruminant and non-ruminant animals. Rumen fluid samples were obtained via stomach tube from sheep and via rumen fistula from cattle 24 h after regular grain feeding. Faecal samples were obtained directly from the rectum of sheep and cattle and from the freshly voided faeces from horses. Samples were processed for the enumeration of lactic acid bacteria following the method of Yankc and Cheng (1998) involving one-hour exposure prior to incubation. A semi-selective MRS-agar medium, Oxoid, England (De Man *et al.* 1960) was modified by adding a freshly prepared reducing solution (1ml containing 0.026g Cysteine, HCl and 0.026g $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$ per 100 ml of media) after boiling then pre-reduced by bubbling with CO_2 on ice until cold. The pH of the medium was adjusted to 5.5 during preparation. Viable colonies from roll tubes were picked and inoculated into a broth of a basal medium 10 (BM 10) as described by Caldwell and Bryant (1966) with glucose (0.5%) and then again cultured in roll tubes. The procedure of picking colonies and inoculating them into a broth medium followed by inoculating again into roll tubes was repeated twice. At 48 h of incubation a drop of the broth medium was examined under the microscope to check the purity of the culture. Morphology and Gram staining characteristics of the isolates were recorded. The ability of cultures to ferment various carbohydrates was evaluated using a broth of BM10 with each isolate included at 2g/L. *S. bovis* was distinguished from *S. equinus* on the basis of their ability to ferment starch, inulin and lactose and their ability to survive heating to 60°C for 30 minutes was also tested (Hardie 1986).

Fermentation products were measured after 24 h of anaerobic incubation of a broth consisting of BM 10 with glucose or starch (0.5%) at 39°C. At the end of the fermentation period, samples from the media were taken for measurement of pH, then acidified with sulphuric acid for further analysis of VFA and lactate. VFA concentrations were measured using a gas chromatograph (Packard Model 427, Packard Instrument Company, Inc, Illinois, USA), fitted with a Chromosorb 'W', acid washed and 60-80 mesh column coated with two liquid phases, a: o-phosphoric acid (1.5% w/w) and b: Polypropylene glycol sebacate (17.5% w/w). The temperature for the

WO 01/02008

PCT/AU00/00805

45

column, detector and the injector were 135, 180 and 210°C respectively. L-lactate and D-lactate were analyzed by auto-analyzer (Cobas Mira Autoanalyser, Roche Diagnostics Inc., French Forest, NSW) using an enzymatic procedure (Stat-PackTM Rapid Lactate Test, Cat. No. 1112 821, Behring Diagnostics Inc., Somerville, New Jersey). The 16S rRNA complete gene sequencing and DNA hybridisation techniques (Lane, 1991) were used to identify the most prevalent strains of *S. bovis*, *Clostridium*-like *vitulinus* and *S. ruminantium*.

Virginiamycin sensitivity test

Two isolates of *S. bovis* from cattle and sheep (orange pigmented and white), five *Clostridium*-like *vitulinus* and three isolates of *S. ruminantium* were incubated in a broth of basal medium 10 with glucose (0.5%) and virginiamycin (VM) at a concentrations of 0, 2, 4, 6 and 8 µg/ml. The virginiamycin solution (100 µg VM/ml) was prepared using Eskalin Writable Powder (WP), 400g/kg VM (Pfizer Animal Health, NSW, Australia). The WP was dissolved in distilled water (previously boiled and bubbled with nitrogen until cooled) and filter-sterilised whilst being gassed with nitrogen. This solution was used immediately after preparation. The lowest concentration of VM that resulted in no measurable growth of the test bacteria was considered as the Minimum Inhibitory Concentration (MIC). The broth-media were inoculated by 0.2 ml of the different fresh viable cultures and 0.1 – 0.4 ml of VM solution was added to each tube to provide the required dose. A sensitivity test was also performed when VM was added 3 and 6 h after inoculation, using the same concentrations of VM. Tests for sensitivity to VM were conducted using 24 and 48 h of anaerobic incubation at 39°C.

DNA extraction, PCR amplification and cloning

Freshly grown cultures were withdrawn from screw-cap Hungate tubes by first flaming the septum with ethanol. Sub-samples (0.6 ml) of liquid culture were taken with a 25G needle and placed in sterile 1.5-mL centrifuge tubes. Cells were harvested as a pellet following centrifugation at 13500 g for 2 min. The supernatant was poured off and the cells resuspended in approximately 30 µL of culture fluid remaining.

DNA was extracted from the concentrated cell suspension using a Fast DNA SPIN Kit (BIO 101, Inc, CA). Extracted DNA was visualized on a 1% TAE gel amended with 0.5 µl of 10mg/mL ethidium bromide per 50 mL agarose. PCR was used to amplify 16S rDNAs in 100 µL reactions. Each reaction tube contained 200 ng of each primer, 10 µl of 10X buffer, 6 µL of MgCl₂, 1U of Tth DNA polymerase (Biotech International, Perth, Australia), 10 µL of 4x0.5mM dNTP's, and the remainder made up with sterile Milli-Q water and 2 µL concentrated cell suspension or DNA extract.

SUBSTITUTE SHEET (RULE 26)

RO/AU

WO 01/02008

PCT/AU00/00805

46

Reactions were overlaid with sterile mineral oil and carried out in a thermocycler (Perkin-Elmer DNA Thermal Cycler 480). Thermocycling parameters employed after a 96°C denaturation for 10 min were 28 cycles of 1 min at 94°C, 1 min at an annealing temperature, and 2 min at 72°C. A further extension step involving 1 min at 48°C and 5 min at 72°C was also employed. The primers used were 27f (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492r (5'-GGTTACCTTGTTACGACT-3') (Lane 1991). In some cases GeneReleaser (Bioventures, Inc., Tennessee, USA) was used according to the manufacturer's instructions in the reactions outlined above. PCR products were purified using a QIAquick PCR purification kit (QIAGEN, Victoria, Australia) according to the manufacturer's instructions.

Sequencing of 16S rDNA

All 16S rDNA samples were initially partially sequenced using the universal 16S rRNA primer, 530f (5'-GTGCCAGCMGCCGCGG-3') and an ABI Big Dye Terminator Cycle Sequencing Ready Reaction Mix kit (Victoria, Australia). Selected 16S rDNA were subsequently fully sequenced on both strands using the following primers: 519r (5'-GWATTACCGCGGCKGCTG-3'), 27f, 907r (5'-CCGTCAATTCMTTTRAGTT T-3'), 926f (5'-AAACTYAAAKGAATTGACGG-3'), and 1492r (Lane, 1991).

Approximately 100 ng of purified PCR product and 25 ng of primer were used in the sequencing reactions. Thermal cycling was carried out in an MJ Research PTC-100 thermocycler with an initial denaturation step of 96°C for 2 min, followed by 25 cycles of 50°C for 15s, 60°C for 4 min, and 96°C for 30s. The resulting cycle sequencing products were purified using the ethanol plus sodium acetate method (ABI, Australia). Purified sequencing products were submitted to the Australian Genome Research Facility for analysis on an Applied Biosystems 377 automated sequencer.

Phylogenetic analysis

Phylogenetic analysis of 16S rDNA's was carried out according to Dojka et al. (1998). Briefly, sequences were aligned and compiled in SeqEd (Applied Biosystems, Australia). Compiled sequences were compared with those on publicly available databases by use of the BLAST (Basic Alignment Search Tool) (Altschul *et al.* 1990) to determine approximate phylogenetic affiliations. Compiled sequences were then aligned using the ARB software package (Strunk *et al.* unpublished) and refined manually. Phylogenetic trees based on comparative analysis of the 16S rRNA genes were constructed by performing evolutionary distance analyses on these alignments using the

WO 01/02008

PCT/AU00/00805

47

appropriate tool in the ARB database. The robustness of the tree topology was tested by performing bootstrapping (2000 replicates) in PAUP test version 4.0d65.

Results

All twenty streptococcal isolates (6 from sheep, 2 from cattle and 12 from horses) were 99% identical in sequence to each other and to *S. bovis* and *S. equinus*. These isolates therefore belong to the genus *Streptococcus* and are members of either *S. bovis* or *S. equinus*. Three of the 12 streptococcal isolates from horses were identified, as *S. equinus* as they did not ferment starch or inulin and only one of them fermented lactose.

Sb R1 was the dominant *S. bovis* strain across all three animal species (cattle, sheep and horse). It grows into bright orange-centred colonies on MRS agar roll tubes and produces an orange pigment in a broth of BM 10 with glucose or starch. The cells are 0.9-1.0 μm in diameter and often encapsulated, occurred mainly in pairs, short chains of 4-10 cells and singles. The doubling time for *S. bovis* was estimated to be 24 minutes. Three streptococcal isolates (SE R1, SE R2 & SE R3) from horses were identified as *S. equinus*. The cells occurred mainly in long chains.

Table 1 shows the fermentation end products of *S. bovis*, *S. equinus*, *Clostridium*-like *vitulinus* and *S. ruminantium* isolates. All of the *S. bovis* bacteria could ferment cellobiose, fructose, galactose, glucose, lactose, maltose, mannose, raffinose, starch and sucrose, but not arabinose, glycerol, mannitol, ribose, sorbitol or xylose and two of the white pigmented isolates did not ferment inulin (Table 2). L-lactate was the main fermentation product of *S. bovis* and *S. equinus*.

The *Clostridium*-like *vitulinus*-like isolates have 100% sequence identity to each other, and 97% identity with *Clostridium*-like *vitulinus*. *Clostridium*-like *vitulinus* cells occurred in different shapes and sizes, mainly straight rods in singles, pairs and short chains and some cells have the tendency to branch. *Clostridium*-like *vitulinus* isolates could not ferment starch or xylose but grew on cellobiose, fructose, glucose, mannose, raffinose and sucrose (Table 2). Two *Clostridium*-like *vitulinus* isolates produced D-lactate and one produced L- and D-lactate at equal proportions.

S. ruminantium was isolated from the rumen of grass-adapted sheep that received a grain supplement with or without virginiamycin. The three *Selenomonas*-like isolates formed two distinct lines of descent: Type A (isolate SR R1); and Type B (isolate SR R2 and isolate SR R3). Type A has 99% identity to *S. ruminantium* and >97% identity to Type B, and Type B has >97% identity to *S. ruminantium*. This indicates that all three isolates are members of the genus *Selenomonas* and Type A belongs to the species *S. ruminantium*. One isolate (SR R1) produced L-Lactate while the other two (SR R2

and SR R3) produced L- and D-lactate (Table 3). A difference between SR R2 and SR R3 was that SR R3 produced 42.5% more lactic acid from starch than SR R2. *S. ruminantium* grew on most carbohydrate sources (Table 2) but their growth was noticeably high on glucose and sucrose compared with other sources and only one isolate (SR R1) did not ferment starch. The cells are $0.5-0.7 \times 1.5-3.0 \mu\text{m}$, occurred mainly in single short crescent rods, with round ends and Gram-negative. Similar amounts of L-lactate were produced from glucose, starch or raffinose by the different *S. bovis* isolates (Table 4).

Incubation *in vitro* of *S. bovis*, *Clostridium*-like *virulinus* and *S. ruminantium* isolates in a broth of Basal Medium 10 with glucose (0.5%) with different concentration of VM (0, 2, 4, 6 and 8 $\mu\text{g/ml}$) clearly demonstrated sensitivity of *S. bovis* to virginiamycin. *Clostridium*-like and *Selenomonas* isolates (Table 5) showed varying levels of resistance to VM. LV R1 and LV R5 were very sensitive to VM with a MIC level of 2 $\mu\text{g/ml}$. Isolates LV R2 and LV R3 resisted levels up to 4 $\mu\text{g/ml}$ and LV R4 up to 6 $\mu\text{g/ml}$. *S. ruminantium* isolates were resistant to the highest VM levels (8 $\mu\text{g/ml}$). Sensitivity of *Clostridium*-like bacteria to VM was different when VM was added at 3 and 6 h after inoculation. All *Clostridium*-like cultures growing for 3 h before the addition of VM had higher MIC than when VM was added to immediately after inoculation. Sensitivity to VM was also lower when assessed using a 48 h incubation. All *Clostridium*-like isolates were resistant to the highest VM levels (8 $\mu\text{g/ml}$) when cultures were allowed to grow for 6 h before the addition of VM.

Discussion

The presence of *Clostridium*-like *virulinus* and *S. ruminantium* in rumen fluid and the faeces of sheep fed diets with or without VM demonstrated the resistance of some *Clostridium*-like strains to virginiamycin (VM). This resistance of *Clostridium*-like and *Selenomonas* isolates has been confirmed by results from anaerobic *in vitro* incubation of in a broth of BM 10 with glucose (0.5%) with or without VM.

A sensitivity test showed that *S. bovis* strains are quite sensitive to VM and this reaction seems to be irreversible and fatal. On the other hand the reaction of *Clostridium*-like cells to VM with may be reversible one and the initial reaction results in only bacteriostasis rather than bactericidal effects.

The fact that the Gram-negative bacteria *S. ruminantium* is not sensitive to VM suggests that there will be situations where are VM may not provide for protection against acidosis. Godfrey *et al.* (1995) and Nagaraja *et al.* (1995) reported that in grain-adapted sheep the inclusion of VM with grain did not prevent decreased ruminal

pH and increased lactate. This may indicate that under conditions where *Clostridium*-like bacteria and *Selenomonas* are well established in the gut, the use of VM may not be as effective in controlling acidosis.

These results also indicate why vaccination against *S. bovis* alone is unlikely to effectively control lactic acid accumulation when animals consume high levels of readily fermentable carbohydrate. Under these are conditions *Selenomonas* and *Clostridium*-like will continue to produce lactic acid even if the activity of *S. bovis* is inhibited.

It is clear that any diagnosis, vaccine or other method to prevent or control fermentative acidosis should detect and or be active against at least *S. ruminantium*, *Clostridium*-like *vitulinus*, *S. bovis* and *S. equinus*.

Example 2

Samples of faeces were collected from 12 horses fed a mixture of chopped lucerne hay and different types of cereal grain (oats, barley, triticale and sorghum). The dominant lactic acid producing bacteria were isolated using the same method as described in Example 1. Two bacteria were isolated: *Streptococcus bovis* (SbR1) and *Streptococcus equinus* (SER1 and SER2). Based on these results it is important that any vaccine, diagnosis or other treatment to prevent or control acidosis should be effective against both *S. bovis* and *S. equinus*. Under some conditions it will also be necessary for these diagnostic tools and methods of treatment to be effective against *S. ruminantium*, *Clostridium*-like *vitulinus* as well as *S. bovis* and *S. equinus*.

In certain conditions it is likely that *Selenomonas ruminantium* and *Clostridium*-like *vitulinus* bacteria may be present and in this case animals should be vaccinated against both Gram-positive and Gram-negative lactic acid producing bacteria.

Example 3

Following calving, cows grazing lush green pasture are exposed to high levels of soluble carbohydrates in the form of fructans in grasses and sugars and starch in clovers. In addition to fermentable carbohydrates in the pasture, concentrate feed supplements, based on cereal grain, are fed twice daily during milking. The fructans in pastures and the starch in legumes and concentrate are rapidly fermented in either the rumen or the hind gut to form a range of volatile fatty acids and lactic acid. The accumulation of acids in the gut contribute to the metabolic acid load of the animal, can cause inflammation of the gut wall leading to stimulation of the immune system and can lead to increased pathogenicity in the populations of bacteria and parasites within the gut. The adverse effects of acid accumulation in the gut result in reduced

WO 01/02008

PCT/AU00/00805

50

productivity and an increased incidence of disease including lameness, respiratory conditions and mastitis.

Acid accumulation in the gut under this dietary regime can be satisfactorily reduced by controlling two of the principle acid producing bacteria *Selenomonas ruminantium* and *Streptococcus* spp. As one of these bacteria is Gram-negative and the other Gram-positive two approaches are used. A vaccine is used to control *Selenomonas ruminantium* and the feed additive virginiamycin is used to control *Streptococcus* spp. The vaccine is prepared by combining washed bacteria of the isolate *Selenomonas ruminantium* (SRR1) (between 10^7 and 10^{11} cells/ml) and 1 ml of the adjuvant DEAE-Dextran. This is injected intramuscularly into dairy cattle prior to calving in order to develop antibodies against *Selenomonas ruminantium* lactic acid producing bacteria. The feed additive virginiamycin is included in the concentrate feed to provide between 150 and 450 mg per head per day.

Example 4

Pigs are often fed diets containing high concentrations of starch and some of this starch can pass undigested to the hind gut where it undergoes rapid fermentation leading to the accumulation of lactic acid. The adverse effects of lactic acid accumulation and low pH in the hind gut of pigs includes metabolic acidosis, compromised integrity of the gut wall and increased pathogenicity of gut organisms. Piglets can be treated against this condition by immunising them against *Prevotella*-like bacteria such as LAB01/07-3, or *Clostridium*-like *vitulinus* and can be further protected by the inclusion of an antibiotic feed additive in the diet such as virginiamycin.

Example 5

Dogs and cats have evolved as carnivorous species but are now fed diets containing processed cereal grain. The carbohydrate fraction of the diet is poorly digested in the small intestine of these animals. Undigested carbohydrate passing from the small intestine to the hind gut is rapidly fermented and result in accumulation of acid. The accumulation of acid and the subsequent adverse side effects can be prevented by vaccination against *Prevotella*-like (LAB03/D35), *Enterococcus*-like (LAB05/D23), *Clostridium*-like *vitulinus* and/or *Selenomonas ruminantium*. Further protection against lactic acid production by *Streptococcus* spp. can be achieved using virginiamycin or similar type of Gram-positive antibiotic compound in the feed.

Example 6

Horses grazing lush green feed and/or supplemented with cereal grain are at risk of incomplete carbohydrate digestion in the small intestine and fermentative lactic acid accumulation in the hind gut. Acid accumulation in the gut can result in laminitis and development of adverse behaviour. The risk of these potential problems can be reduced by immunisation against *Streptococcus equinus* and the strategic use of antibiotics active against *Clostridium*-like *vitulinus* and *Selenomonas ruminantium*.

Example 7

Humans suffering from lactose intolerance, irritable bowel syndrome, or any side effects of acidic gut syndrome can be immunised against *Clostridium*-like *vitulinus* and/or *Selenomonas ruminantium* and treated strategically with antibiotics such as virginiamycin and probiotics such as *Megasphaera elsdeni*, *Bifidobacteria*, Lu12 or Su109.

Example 8

1. Seroconversion in sheep vaccinated with bacterin comprised of formalin-killed lactic acid producing bacteria

An experiment was conducted to examine whether sheep would raise antibodies in response to a range of bacterins comprising bacteria that are commensal organisms in the gastrointestinal tract of ruminants or horses.

Materials and methods

Forty nine adult Merino wethers (approximately three years of age) were checked for uniformity and physical appearance before entering the study. All animals were weighed and treated against internal parasites (ivermectin) approximately 3 weeks before being randomly assigned to one of seven experimental groups (seven animals per treatment group). Each animal received a different vaccination treatment consisting of one of the bacterins described in Table 8.1 and animals in the control group received adjuvant only. All of the sheep remained at pasture for 34 weeks before being housed for a grain challenge experiment. During the grazing phase of the experiment the sheep were given access to good quality green pasture whenever possible.

Table 8.1 Details of microorganisms used in vaccine preparation

	Microbe	Expt. ID code	Accession No.	Date of Deposit
1.	<i>Streptococcus bovis</i>	Sb5	N94/8255	8 March 1994
2	<i>Streptococcus bovis</i>	A2	NM99/04455	24 June 1999

WO 01/02008

PCT/AU00/00805

52

3	<i>Streptococcus equinus</i>	Scq	NM99/04457	24 June 1999
4	<i>Clostridium-like vitulinus</i>	LV	NM99/04462	24 June 1999
5	<i>Selenomonas ruminantium</i>	SR1	NM99/04458	24 June 1999
6	<i>Selenomonas ruminantium</i>	SR2	NM99/04460	24 June 1999

Preparation of vaccines: Frozen isolates of all bacteria were thawed then cultured in BM 10 for between 6 and 10 hours. All incubations were at 37°C. Formalin was added to the incubation flasks to achieve a final concentration of 0.5% in the final solution. The cells were then harvested by centrifugation and washed 3 times using sterile PBS before being made to final volume in PBS with a concentration of 5×10^9 cells/ml.

The vaccines were prepared by mixing equal volumes of the bacterial suspension and Freund's complete adjuvant in the case of the primary vaccinations and Freund's incomplete adjuvant for booster injections. The control animals received sterile PBS and adjuvant. Each vaccination injection was 2 ml administered intramuscularly. For the primary and secondary vaccination each sheep received 4 injections, one in each shoulder and 1 into each of the semi-membranosa muscles of each hind leg. The booster given in the 35th week after the primary injection was only administered to the two hind legs.

Samples of blood were taken according to the schedule in Table 8.2 for measurement of antibodies against the bacterin used to vaccinate each treatment group. Development of ELISA methods for measurement of relevant antibody titres was an important component of this study and is described below.

ELISA protocol: Bacterial antigen was prepared in the same way as described for the immunisations, and stored in aliquots at -20°C. Optimal antigen dilution was found to be 1:260 (diluted in carbonate buffer); 100 µl of this suspension was added to each well of ELISA plates (Immunolon II flat bottom 96-well plates). Plates were then covered and incubated overnight at 4°C. Antigen was removed from the wells and the plates washed 3 times in PBST (NaCl 8g, KCl 0.2 g, Na₂HPO₄ 1.15g, KH₂PO₄ 0.2g, 0.5 ml Tween 20, in 1000 ml MQ water, pH 7.2-7.4) using an automated plate washer (TiterTek Microplate Washer 120, Flow Laboratories). Blocking buffer (1% Bovine serum albumin (Sigma) in PBST) was added to each well and allowed to incubate at 37°C for 1 hour, followed by 3 washes with PBST. Titrations of the test sera were performed and optimal dilutions for a standard assay determined. Test sera were analysed by diluting sera in blocking buffer at levels found to be optimal for each antigen. Following dilution 100 µl of each test serum was analysed in duplicate wells: in addition, pre-vaccination serum was always included in each plate. Negative controls (PBS) and standards were included in triplicate.

SUBSTITUTE SHEET (RULE 26)

RO/AU

Standards were prepared by double serial dilution (in blocking buffer) starting at 1:100 of previously-assayed sheep sera known to contain Sb5 antibodies. After adding the serum samples, plates were incubated for 1 hour at 37°C followed by 3 washes in PBST. The optimal dilution of the horseradish peroxidase conjugates was found to be 1:1,000 for the sheep (rabbit anti-sheep-IgG (H & L) HRP, BioRad). Conjugates were diluted accordingly in blocking buffer, 100 µl added to appropriate wells, and the plates incubated for 1 hour at 37°C. Plates were again washed 3 times with PBST, and 100 µl of substrate added (34 mg o-phenylenediamine in 100 ml citrate phosphate buffer (light sensitive), 50 µl of 30 % H₂O₂ (added just prior use) (citrate phosphate buffer: citric acid 7.3 g, Na₂HPO₄ 9.5 g, 800 ml MQ water, pH to 6 with 10 M NaOH and brought to 1000 ml). Plates were incubated in the dark at room temperature for 30 mins at which time the enzymatic reaction was stopped by the addition of 100 µl of 2N sulphuric acid. Absorbances were read in a microplate reader (Benchmark, BioRad) and the data analysed using Microplate Manager/PC 4.0 (BioRad) software. Analysis parameters and standard curve information were included for each plate.

Samples of rumen fluid were taken via stomach tube and pH was measured before taking a sub-sample for determination of potential lactic acid production. The remainder of the sample was acidified for later measurement of volatile fatty acid concentrations. Potential lactic acid production was measured by incubating 4 ml of rumen fluid with 1 ml glucose solution containing 50 mg glucose/ml. Following incubation with glucose for 20 hours pH was measured before acidification with 0.1 ml of concentrated sulphuric acid and frozen for subsequent analysis of lactic acid concentration.

Table 8.2 Schedule of immunisation and sampling to monitor systemic antibody levels and the consequences of vaccination in Example 8

Week	Procedure
-1	Blood sample (First pre-bleed)
0	Blood sample (Second pre-bleed) + primary immunisation
2	Blood sample for antibody measurement
4	Blood sample + secondary (first booster) immunisation
6	Blood sample + collect rumen fluid and faeces
8	Blood sample
10	Blood sample + collect rumen fluid and faeces
12	Blood sample
14	Blood sample

WO 01/02008

PL 1/1 0/00007

54

For bacterial enumeration rumen fluid samples were processed following the one-hour exposure method prior to incubation of Yanke and Cheng (1998). The rumen fluid was serially diluted ten-fold in anaerobic dilution solution (ADS) (Caldwell and Bryant, 1966) to a final dilution of 10^{-8} . Three dilutions (10^{-6} , 10^{-7} and 10^{-8}) were used to inoculate the media roll tubes in triplicate for each dilution. A modified semi-selective MRS-Agar medium, Oxoid, England (de Man *et al.*, 1960) was used to culture the lactic acid bacteria with the pH of the medium adjusted to 5.5. The tubes were incubated at 39°C for three days. Faecal samples collected directly from the rectum were mixed with two times their weight of distilled water. 4 ml of the slurry was incubated with glucose solution as described for rumen fluid potential lactic acid measurement. A further quantity (approx 10 ml) was filtered through 4 layers of cheese cloth before measuring pH and then acidifying the sample for later analysis of volatile fatty acids.

VFA concentrations measured by gas chromatography (Hewlett-Packard) and L(+)lactate and D(-) lactate analyzed by auto-analyzer (Cobas Mira Autoanalyser, Roche Diagnostics Inc., French Forest, NSW) using an enzymatic procedure (Stat-Pack™ Rapid Lactate Test, Behring Diagnostics Inc., Somerville, New Jersey).

Results

There were good levels of seroconversion (see Table 8.3) in response to the various bacterins used in this experiment and elevated antibody titres persisted to week 14 following the primary vaccination.

Table 8.3 Antibody titres (Ab units x 1000) measured in serum from sheep immunised with different bacterin. Time in weeks refers to weeks after the primary vaccination. All sheep were re-immunised 4 weeks after the primary vaccination.

Streptococcus bovis; *Streptococcus equinus*; *Clostridium-like vitulinus*; *Selenomonas ruminantium* isolates R1 and R2 respectively

Group	Sheep	Bacterin	Prc vacc'n	Week 2	Week 4	Week 6	Week 8	Week 10	Week 12	Week 14
1	1	<i>S. bovis</i> Sb5	0	0	0	240	0	166	271	807
1	3	<i>S. bovis</i> Sb5	0	0	0	0	0	0	0	296
1	5	<i>S. bovis</i> Sb5	0	0	0	462	224	700	381	0
1	6	<i>S. bovis</i> Sb5	0	114	183	557	224	370	405	386
1	7	<i>S. bovis</i> Sb5	88	178	296	1,136	620	490	588	538

WO 01/02008

PCT/AU00/00805

55

2	8	<i>S. bovis</i> A2	0	28	70	311	100	294	712	528
2	9	<i>S. bovis</i> A2	0	0	25	181	116	232	2,714	712
2	10	<i>S. bovis</i> A2	11	14	37	181	218	187	1,094	498
2	11	<i>S. bovis</i> A2	0	8	25	121	175	329	3,567	3,567
2	12	<i>S. bovis</i> A2	9	24	25	120	81	79	1,823	1,321
2	13	<i>S. bovis</i> A2	6	11	15	64	99	110	1,823	2,904
2	14	<i>S. bovis</i> A2	12	33	44	197	227	180	3,567	2,220
3	15	<i>S. equinus</i>	9	22	85	105,000	2,011	5,197	10,140	5,622
3	16	<i>S. equinus</i>	10	11	20	302	80	38	23	18
3	17	<i>S. equinus</i>	8	9	11	484	558	871	3,657	3,936
3	18	<i>S. equinus</i>	9	28	123	300,000	18,710	27,010	265,900	73,440
3	19	<i>S. equinus</i>	9	28	161	6,367	4,430	971	385	784
3	20	<i>S. equinus</i>	9	10	53	2,225	191	824	501	1,250
3	21	<i>S. equinus</i>	9	13	33	797	109	90	67	101
4	22	<i>C. vitulinus</i>	13	206	98	883	477	899	324	1,221
4	23	<i>C. vitulinus</i>	33	115	142	394	244	265	100	89
4	24	<i>C. vitulinus</i>	1,014	202	265	103	130	43	45	554
4	25	<i>C. vitulinus</i>	127	145	365	1,181	477	394	365	159
4	26	<i>C. vitulinus</i>	0	0	313	2,948	243	634	313	234
4	27	<i>C. vitulinus</i>	0	483	292	1,944	668	1,197	2,898	1,446
4	28	<i>C. vitulinus</i>	0	243	417	123	469	602	243	0
5	29	<i>SR R1</i>	17	125	120	181	246	1,346	829	688
5	30	<i>SR R1</i>	16	446	172	229	303	392	441	396
5	31	<i>SR R1</i>	2	261	300	261	114	89	648	441
5	32	<i>SR R1</i>	15	145	115	545	16,130	5,058	40,660	24,140
5	33	<i>SR R1</i>	21	159	124	241	145	124	127	92
5	34	<i>SR R1</i>	0	55	46	132	132	67	86	83
5	35	<i>SR R1</i>	0	83	67	109	94	170	384	563
6	36	<i>Sr R2</i>	0	117	3,292	3,403	2,570	9,975	4,367	3,132
6	37	<i>Sr R2</i>	7	14	49	110	261	227	249	351
6	38	<i>Sr R2</i>	6	12	63	329	619	430	1,156	512
6	39	<i>Sr R2</i>	6	51	110	210	169	261	437	1,450
6	40	<i>Sr R2</i>	8	23	78	723	913	12,000	3,240	1,174
6	41	<i>Sr R2</i>	10	19	72	107	185	322	88	124
6	42	<i>Sr R2</i>	8	30	2,255	11,940	432	235	214	442

WO 01/02008

PCT/AU/00805

56

During the period that sheep were grazing spring and summer pastures there was no significant effect of vaccination treatment on faecal dry matter content, as an index of faecal consistency and diarrhoea (see Table 8.4). Although not statistically significant there were more lactic acid bacteria (growing on MRS medium) in the rumen fluid of sheep immunized against the *S. ruminantium* bacteria. This is an important result and is consistent with the pH of rumen fluid shown in Table 8.5 (week 10) and Table 8.6 (week 38) where the treatment groups with highest numbers of lactic acid producers were found to have lowest pH.

Table 8.4. Body weight of sheep at week 34 and the faecal dry matter % measured during weeks.

	Body weight (Week 34)	Body weight Week 34 SE	Faecal dry matter (Week 0)	Faecal DM Week 0 SE	Faecal dry matter (Weeks 6 & 10)	Faecal DM Weeks 6 & 10 SE
Sb5	56.2	2.87	23.7	1.86	25.0	1.617
A2	52.9	2.42	21.4	1.93	22.5	1.810
Seq	54.0	0.75	23.8	2.60	22.1	1.760
LV	56.0	1.54	22.4	1.36	22.3	1.803
SR1	54.4	1.83	24.8	1.26	22.5	1.803
SR2	56.3	1.83	24.7	2.15	24.2	1.393
Control	56.5	1.44	26.4	2.63	22.6	0.998

Table 8.5 Rumen and faecal pH and the pH following incubation with glucose in samples taken from vaccinated sheep 6 and 10 weeks following vaccination with a range of lactic acid-producing bacterins. Numbers of bacteria (cells/ml) measured in the rumen fluid during week 10.

	Rumen pH	SE	Faecal pH	SE	Total bacteria $\times 10^8$	Lactic acid bacteria $\times 10^7$	Lactic acid bacteria % of total
Sb5	7.0	0.075	7.7	0.77	10.1	8.5	9.1
A2	7.0	0.075	7.4	0.77	1.5	9.2	6.2
S.Eq	6.9	0.075	7.6	0.77	1.3	6.7	5.4
LV	7.0	0.075	7.6	0.77	1.3	6.8	5.7

WO 01/02008

PCT/AU00/00805

57

SR R1	6.9	0.075	7.7	0.77	2.1	46.5	12.7
SR R2	6.9	0.075	7.5	0.77	2.8	22.0	6.3
Control	6.9	0.078	4.5	0.80	1.5	11.9	7.9

2. Response to grain acidosis challenge in sheep 38 weeks after initial immunisation

Thirty four weeks after the primary vaccination all sheep were brought into the animal house where they were weighed and housed in individual pens with free access to clean water. All animals were treated with a broad-spectrum anthelmintic. For a period of four weeks animals were fed a mixture of cereal & lucerne chaff (1100g/d).

Five days after entering the shed sheep were re-vaccinated as described above and were given approximately 60 g wheat/d together with 1100 g chaff. During week 37 (post primary vaccination) samples of rumen fluid and faeces were taken for measurement of pH and potential lactate production. Portion of the samples were also taken for later analysis of volatile fatty acids.

Grain challenge and sampling: On day 1 of the challenge, 1 kg of whole wheat was offered to each sheep at approximately 7 AM. For those sheep that had not eaten all the wheat within 2 hours an amount of cracked wheat equivalent to the residue and was administered into the rumen via stomach tube as a slurry made up with water. Immediately after administration of the wheat, blood samples were taken for antibody measurements and for haptoglobin determination. Approximately eight hours after first feeding the wheat (4 PM), samples of rumen fluid were taken for measurement of pH, VFA and lactate.

On the following morning a rumen sample was taken for measurement of pH, VFA and lactate and a check made of faecal consistency (faecal scores). Faecal samples were collected for measurement of pH and dry matter. All sheep were then offered 500 g wheat and 1 hour later refusals weighed. An amount of cracked wheat equivalent to the residue was administered into the rumen via a stomach tube. Chaffed lucerne and cereal hay was fed ad libitum after the final dose of wheat and intakes were measured daily. Samples of rumen fluid were taken 8 hour later (32 h from first wheat) and faeces were scored for consistency and sampled for pH. Forty eight hours after first offering wheat to the sheep a final rumen sample was taken and faecal scores were recorded. A sample of blood was taken for haptoglobin analysis.

Results

WO 01/02008

PCT/AU00/00805

58

Antibody levels, rumen pH and the potential lactic acid production measured during week 38 after primary challenge (4 weeks after the second booster injection administered during week 34) are summarised in Table 8.6. The major finding is that the rumen pH pre-grain challenge and on "normal" feed was significantly ($P < 0.001$) affected by vaccination treatment. The control animals had the highest level of acid and the group vaccinated with Sb A2 had the lowest acidity (highest pH). These data strongly suggest an effect of vaccination on acid production during rumen fermentation on normal diets.

In vivo responses to the "intake" of excessive levels of wheat are summarised in Table 8.7. There were significant ($P < 0.01$) differences in rumen lactic acid concentrations with the sheep vaccinated with Sb A2, vitulinus (LV) and SR2 having the lowest concentrations of lactic acid in the rumen.

Faecal consistency scores were significantly ($p < 0.01$) different in sheep vaccinated with different antigens. The sheep vaccinated against *S. equinus* consistently had more diarrhoea than the other treatment groups and these sheep also had the lowest feed intake.

Table 8.6 Antibody titres (Ab units \times 1000) at week 38, rumen fluid pH and potential lactate production measured in rumen fluid and faeces.

* Animals in the control group had antibodies against LV at a level $< 2\%$ of the group vaccinated against LV, and no antibodies against other antigens used in this experiment.

Treatment	Antibody titre	Rumen fluid	Potential lactate	Potential lactate Faeces
	Week 38	pH Week 38	Rumen Week 38	Week 38
Sb5	260	7.02	27.3	18.9
A2	30	7.09	19.1	25.2
Seq	15	6.95	18.6	24.7
LV	3492	6.90	16.8	19.7
SR1	496	6.75	23.4	28.8
SR2	690	6.82	13.6	19.1
control	0*	6.89	30.6	27.2
Sig	0.001	0.001	NS	NS
SE	314	0.078	6.0	3.5

Table 8.7 Responses in vaccinated sheep to grain acidosis challenge. Faecal consistency score were based on 1 = normal pelleted faeces and 5 = diarrhoea. Feed intake values are: g/d.

Treatment	Rumen lactate (32 h after wheat)	Rumen pH (32 h after wheat)	Faecal pH (24 h after wheat)	Average faecal score 24 to 48 h after first wheat	Average feed intake for 72 h after first wheat
Sb5	25.5	5.81	6.51	1.73	674
A2	0.6	5.99	5.54	3.31	639
Seq	56.3	5.65	5.90	3.73	516
LV	0.0	5.91	5.48	2.77	599
SR1	19.3	5.83	6.19	2.25	665
SR2	2.1	5.83	5.67	3.39	697
Control	0.1	6.16	5.75	2.31	786
Sig	0.01	NS	NS	0.01	NS
SE	12.7	2.1	0.45	0.38	69

Discussion

The results of this study have shown that it is possible to immunise sheep against aggressive lactic acid producing bacteria that normally inhabit the gastrointestinal tract and that by producing antibodies to these lactic acid producing bacteria the animal is able to alter the response to dietary carbohydrate overload. Changes in response to the grain overload challenge include reduced amounts of rumen lactic acid accumulation in sheep vaccinated with A2, SR2 and Cv. Sheep in these treatment groups had the lowest levels of lactic acid of the vaccinated sheep. The treatment group with the highest rumen lactic acid (*S. equinus*) had the lowest subsequent feed intake and the most severe diarrhoea.

It is concluded that lactic acid bacteria other than Sb 5 can be used as antigens to alter the animals ability to respond to fermentative acidosis challenge and that other bacteria such as A2, Cv and SR2 may actually be more effective antigens in preparing the animal to control lactic acid build up in the rumen following a carbohydrate challenge. The only bacterial antigen used in this study that was not isolated from a ruminant animal (*S. equinus*, isolated from a horse) had the least effect in reducing lactic acid

WO 01/02008

PCT/...00/00805

60

accumulation. This indicates the importance of discovering and isolating the lactic acid producing bacteria specifically associated with type of animal and relevant diet.

Example 9

Isolation of predominant and aggressive lactic acid producing bacteria from the digestive tract of pigs, dogs and humans.

The lactic acid producing bacteria in the hind gut or large bowel (caecum, colon and rectum) of different vertebrate species vary depending on the substrate available for fermentation and the rate of turnover of digesta in the large bowel as this determines average residence time of bacteria in the large bowel. The amount and nature of substrate entering the large bowel is determined by two major factors: diet and the pre-digestion of dietary substrates in the stomach and small intestine prior to passage of digesta into the large bowel. Pre-digestion in the stomach and small intestine are, in turn, are influenced by the nature and efficiency of digestive enzymes (such as amylase, amyloglucosidase, pepsin, pepsinogen, brush-border carbohydrate degrading enzymes), rate of intake and effective of chewing and particle size diminution such as occurs in the crop of bird, the rate of digesta passage (determined by factors such as animal species, meal size, level of stress) and the absorptive capacity of the digestive tract. The rate of turnover of digesta in the large bowel is determined by the size of compartments such as the caecum and colon relative to the flow of digesta through the compartments. The half-time for digesta residence in different animal species can vary from days to just several hours. Variation in residence time and the amount and nature of substrate available for fermentation in different vertebrate species, consuming different diets, therefore means that there will be important differences in the dominant lactic acid producing bacteria that colonise the large bowel.

Even in situations where it is well known that a species of bacteria such as the lactobacilli or streptococci produce lactic acid it is essential to discover and isolate the actual strains of that genus specifically capable of surviving in the particular digestive compartment under the prevailing conditions of flow and substrate availability with the ability to compete with other gut bacteria. Moreover it is essential to identify and select the strain(s) numerically important and capable of abundant lactic acid production. The experiments described below were designed to discover and isolate the predominant lactic acid producing bacteria from the digestive tract of pigs, dogs and humans. Since there are no major physiological changes in the pH, temperature or anaerobic/aerobic status of digesta during passage from the caecum through the colon and rectum, samples of faeces

WO 01/02008

PCT/AU00/00805

61

were considered to provide suitable material for isolating the lactic acid bacteria of the large bowel of the respective vertebrate species.

(i) Discovery and isolation of lactic acid producing bacteria from pigs

Commercial diets for pig production are commonly based on cereal grain. The grain is normally processed by grinding through a hammer mill before mixing with protein, vitamins and minerals to form a complete diet. In the current study samples of faeces were taken from 5 pigs in a commercial piggery. The pigs weighing around 40 kg and 6 weeks of age were housed in group pens and were considered to be in good health with no signs of abnormality at the time of sampling. The diet contained barley and sorghum (50:50 by weight) as the source of grain and was formulated to contain 14% protein. The level of feeding was designed to be ad libitum and was offered to the animals twice per day.

Faeces were prepared as described in Example 1 for the discovery and isolation of the most numerous species/strains of lactic acid bacteria. The process of selecting colonies for dominance and lactic acid production and isolating pure strains involved enumeration of lactic acid strains on a modified semi selective MRS and growth in a broth of glucose based BM 10 as described in Example 1. Those isolates considered the most important lactic acid producers were studied microscopically for purity and gross morphological classification.

There were 2 isolates considered to be different from lactic acid producing microbes isolated in our previous research. These isolates are described in Table 9.1 and have been deposited with the Australian Government Analytical Laboratories (AGAL). Dates and accession numbers are summarised in Table 9.1

Table 9.1 Details of two lactic acid-producing bacterial isolates discovered in the faeces of pigs under commercial piggery conditions.

Lab code number	LAB 01/07-3	LAB 02/11-2
Description	Short rods arranged in short chains and filaments, Gram +	Short straight rods with round ends, also long thin rods
Preliminary classification	<i>Prevotella</i> -like	non-slime producing lactic acid bacterial isolates
AGAL accession number	NM00/12630	NM00/12631
Date of AGAL deposition	29 June 00	29 June 00

(ii) Discovery and isolation of lactic acid producing bacteria from dogs

WO 01/02008

PC1...J00/00805

62

Two experiments were undertaken to identify the most important lactic acid bacteria in the large bowel of dogs on a high carbohydrate diets fed with, or without, the antibiotic feed additive virginiamycin. As indicated in Example 1 there are situations where the antibiotic feed additive virginiamycin produces incomplete control over lactic acid accumulation in the digestive tract of ruminant animals. The experiment outlined below was undertaken to determine the level of control of virginiamycin over lactic acid accumulation in the large bowel of dogs. The second experiment in this Example 9 was designed to discover and isolate the dominant lactic acid producing bacteria from the faeces of dogs fed the same diet either with or without virginiamycin.

1. **Does virginiamycin control lactic acid production in the large bowel of dogs?**

The main objective of this trial was to investigate various doses of virginiamycin in terms of its effect on faecal consistency and hind gut fermentation.

Design: There were 4 treatment groups consisting of unmedicated control, and virginiamycin at 3 levels: 0.25, 0.5 and 1 mg/kg body weight. Dogs were acclimatised to a diet based on the tinned 'No Frills' dog food for approximately 2 weeks prior to a seven-day treatment period in which fructo-oligosaccharide rafilose was added to the diet at a rate of 3.5 g/kg metabolic body weight. There were five dogs per treatment.

Measurements were made of faecal pH, dry matter, consistency and chemical assays were conducted to measure VFA, D- lactic acid and L- lactic acid.

Results The main results are summarised in Table 9.2.

- The effect of rafilose inclusion is to reduce pH by approximately 1 unit. The secondary effects associated with the increased acidity include more sloppy consistency, reduced dry matter and increased lactic acid.
- There was little effect of the virginiamycin on the pH, faecal consistency, dry matter content and VFA concentrations. The only clear effect of virginiamycin in this experiment was to reduce the concentration of d-lactic acid. Virginiamycin had this effect on the lactic acid at all levels of inclusion.

Table 9.2 Summary of faecal pH and lactic acid concentrations in dogs fed a diet of tinned "No Frills" dogs food and added rafilose. A consistency score of 5=firm, normal faeces and 1=diarrhoea

	Pre-Rafilose (mean all dogs)	Control No VM	VM 0.25	VM 0.5	VM 1.0	Treat signif

WO 01/02008

PCT/AU00/00805

		63				
pH	6.0	5.4	5.2	4.9	4.9	
Consistency	5.0	3.4	3.6	3.7	3.8	
Dry matter	25.0	20.5	22.0	22.5	24.2	
L-lactic	0.6	11.5	2.2	13.8	11.8	
D-lactic	0.1	8.5	0.2	0.4	0.3	**
Total VFA	88.0	80.0	80.5	93.7	73.5	

Discussion : There were high concentrations of VFA in all treatment groups irrespective of whether or not rautilose was included in the diet. It is likely that this high level of VFA has an overriding effect on pH and masks the potential beneficial effects of reduced D-lactic acid associated with the inclusion of virginiamycin. The observation that virginiamycin reduced D-lactic acid but had little effect on L-lactic confirms that virginiamycin does not always inhibit all lactic acid bacteria.

2. Discovery and isolation of lactic acid bacteria from dogs

Two dogs were fed a commercial dry dog food for 4 weeks before and then during the experimental period. Virginiamycin (Eskalin 20) was added to the diet of one dog for a period of 7 days prior to faecal sampling to provide 0.5 mg/kg body weight. Samples of faeces were taken for the analysis of pH and lactic acid concentrations at the same time as those taken for isolation of lactic acid producing bacteria.

Isolation and purification of the lactic acid bacteria was achieved using the methods previously described in Example 1. Two lactic acid bacteria were isolated from the dog not treated with virginiamycin and a further two from the dog treated with virginiamycin (see Table 9.3)

Table 9.3 Characteristics of faeces and details of the lactic acid producing bacteria isolated from dogs.

	Control (no virginiamycin) "M"		Virginiamycin "T"	
L(+)Lactate	2.55 mmol/L		0.34 mmol/L	
D(-)Lactate	2.06 mmol/L		0.45 mmol/L	
Faecal pH	5.49		5.34	
Lab code No.	LAB 03/D 35	LAB 04/D37	LAB 05/D23	LAB 06/D29
Description	Predominantly rods in filaments. (Gram+)	Predominantly large cocci, occurring mainly in pairs and singly (larger than the <i>S. bovis</i> isolates SB R1 (Gram +))	Predominantly small cocci < than 1 µm in diameter mainly as diplococci (Gram +)	Long > than 5µm thick rods, in singles and short chains.
Preliminary classification	Prevotella-like	Streptococcus-like	Enterococcus-like	Non-slime producing lactic acid isolate
Accession No	NM00/12632	NM00/12633	NM00/12634	NM00/12635
Despot date	29 June 00	29 June 00	29 June 00	29 June 00

(iii) Discovery and isolation of lactic acid bacteria from human

An experiment was conducted to discover and isolate the most important lactic acid producing bacteria from the large bowel of a human subject in good health and consuming a normal balanced diet with a range of different sources of carbohydrate (bread, pasta, rice and potato), various sources of protein (plant and animal origin) and a range of fruit and vegetables providing soluble and insoluble non-starch polysaccharides. The methods used to isolate the most important lactic acid bacteria were as described in Example 1.

The pH of the faecal sample was 6.5 and there were very low levels of lactic acid (1.0 mmol/kg L(+) lactate). Descriptions of the two dominant lactic acid producing isolates are given in Table 9.4 together with details of the AGAL lodgement.

Table 9.4 Description of the lactic acid producing bacterial isolates from human faeces

Lab code of lactic acid isolate	<i>LAB 07/H1</i>	<i>LAB 08/H15</i>
Description	Predominantly short rods forming filaments	Endospore-forming bacteria, rod shaped, straight with spores. (Gram +)
Preliminary classification	Bacteriodes-like	Non-slime producing lactic acid isolate
AGAL accession No.	NM00/12636	NM00/12637
Date of AGAL deposition	29 June 00	29 June 00

Example 10

Isolation of lactic acid producing bacteria from the stomach

While most lactic acid production as a result of fermentation of carbohydrate takes place in the large bowel or hind gut it is also possible for fermentation and acid accumulation to occur in the stomach of some vertebrate species. Acid accumulation in the stomach can be important in development of ulcers in the stomach. While acidic damage is generally considered to be a result of acid secreted by the stomach. It is generally considered that the true stomach of monogastric animals and humans is too acidic (around pH 2) for growth and persistence of most bacterial species. It is certainly not considered that bacterial fermentation in the stomach contributes to the acid load in that digestive compartment. However there are non-acid secreting regions in the stomach of most monogastric animals and it is in these parts that lactic acid producing bacteria to survive. In some vertebrates, including the horse, food can be held in the stomach for several hours. Under these conditions it is possible that bacteria capable of surviving

WO 01/02008

PCT/AU00/00805

65

acidic conditions while fermenting carbohydrate may contribute to the acid load in the stomach.

An experiment was conducted to determine if lactic acid bacteria occur the stomach of a horse consuming grain. A horse was fed a diet consisting of pasture and 2 kg/d of ground wheat grain for 2 weeks before it was humanely killed. Contents of the stomach were removed and sampled for isolation of dominant lactic acid producing bacteria using methods described in Example 1.

A mixed culture of lactic acid bacteria was discovered and isolated from the stomach contents. There were numerous colonies even at 10^{-8} dilution and lactic acid production was predominantly L(+) lactate. The purification of individual strains has not yet been completed.

The results of this experiment show that lactic acid producing bacteria in the stomach of monogastric animals other than horses may have an important role in contributing to the acid load in the stomach that is responsible for ulcer formation in a wide range of intensively fed and managed domestic animals as well as humans. Isolation of these strains, using the methods described in Example 1, is likely to yield strains of lactic acid bacteria with important roles in vaccine preparation, diagnostic methods and developing pharmaceutical preparations.

Example 11

Vaccination of horses with the combination of *S. bovis* (Sb R1 A2) and *Streptococcus equinus* (SE R2)

Seven horses grazing senescent winter pastures were treated against internal parasites using a broad spectrum ivermectin drench three weeks before the start of the experiment. At the start of the experiment three of the horse were vaccinated against the lactic acid producing bacteria: *S. bovis* (strain Sb R1 - A2) and *S. equinus* (strain SE R2). Three weeks after the primary vaccination the secondary vaccination was administered. Samples of blood and faeces were taken prior to vaccination, at the time of the secondary vaccination and again 2 weeks later.

Vaccine preparation and procedure: Pure isolates of *S. bovis* and *S. equinus* were thawed and cultured in Basal Medium 10 at 37° . Formalin was added to the cultures at the end of the growth phase to achieve a final concentration of 0.5%. The cells were harvested by centrifugation at 17,000 g for 20 minutes. The supernatant was discarded before re-suspending the cells in sterile PBS followed by centrifugation. The cells were washed 3 times in this way before being counted and made to a final volume in sterile PBS containing 1×10^{10} cells/ml. Prior to vaccination equal volumes of each bacterial

WO 01/02008

PCT/AU00/00805

66

suspension were mixed. The mixed bacterial suspension was then combined with aluminium hydroxide adjuvant (Alhydrogel 1.3%) in equal volumes. The vaccine was administered subcutaneously on the neck of each horse (2 ml per injection with 5×10^9 cells of each bacteria per injection). Following each injection horses were regularly checked for any side effects of the vaccination and the injection site monitored by measurement.

Results: The site reaction to the vaccine was clearly observed in all horses and decreased in volume to around 10 ml within 48 h for the primary injection and 96 h for the secondary vaccination. No adverse side effects were observed during the period of monitoring following vaccination.

Table 11.1 Site reaction (volume in ml of subcutaneous oedema) following primary and secondary vaccination into the neck of horses with the dual bacterin Sb A2 and SE R2

Horse ID	Primary vaccination		Secondary vaccination		
	24 h	48 h	24 h	48 h	96 h
1	12	12	59	36	9
2	54	15	90	20	9
3	5	5	56	6	6
Average:	23.7	10.7	68.2	20.5	8.0
SE	15.3	3.0	10.9	8.8	1.2

Table 11.2 Antibody levels (ELISA absorbance) against *S. bovis* (A2) and *S. equinus* in serum from vaccinated horses

Horse ID	<i>S. equinus</i> (SE R2)			<i>S. bovis</i> (A2)		
	Pre-vaccination	Week 3	Week 5	Pre-vaccination	Week 3	Week 5
1	0.099	0.087	0.110	0.053	0.053	0.087
2	0.097	0.086	0.135	0.048	0.100	0.130
3	0.088	0.128	0.165	0.060	0.096	0.129
Average:	0.095	0.100	0.137	0.054	0.083	0.115
SE	0.003	0.014	0.016	0.003	0.015	0.014

There was good seroconversion and consistent antibody production against both bacterins in all horses (Table 11.2). The seroconversion and antibody levels measured in

WO 01/02008

PCT/AU00/00805

67

serum are consistent with the site reaction detailed in Table 11.1 and demonstrate efficacy of vaccination using dual lactic acid bacterins.

Conclusion: Multiple bacterin vaccines against lactic acid bacteria are effective in producing seroconversion and consistent antibody responses to both antigens.

Industrial Applicability

The present invention makes use of a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotellu*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

WO 01/02008

PCT/AU00/00805

68

Table 1 Fermentation products of *Streptococcus bovis*, *Streptococcus equinus*, *Clostridium-like vitulinus* and *Selenomonas ruminantium* isolates in a broth of basal medium 10 with glucose (0.5%).

Isolate	End products
<i>Streptococcus bovis</i>	L - Lactic [†]
<i>Streptococcus equinus</i>	L - Lactic
<i>Clostridium-like vitulinus</i> (LV R1, LV	D - Lactic
<i>Clostridium-like vitulinus</i> (LV R3)	L - Lactic, D - Lactic
<i>Selenomonas ruminantium</i> (SR R1)	L - Lactic Acetic, Propionic
<i>Selenomonas ruminantium</i> (SR R2)	L - Lactic, D - Lactic, Acetic,
<i>Selenomonas ruminantium</i> (SR R3)	L - Lactic, D - Lactic, Acetic,

†, Bold indicates main fermentation product.

WO 01/02008

PCT/AU00/00805

69

Table 2 Fermentation of carbohydrate substrates by *S. bovis*, *S. equinus*, *Clostridium*-like *vitulinus* and *S. ruminantium* isolates from pasture-adapted sheep supplemented with wheat grain plus urea.

Carbohydrate	Bacterial Isolates		<i>Clostridium</i> -like <i>vitulinus</i>					<i>S. ruminantium</i>			
	<i>Streptococcus</i>										
	<i>S. bovis</i>	<i>S. equinus</i>	LV R1	LV R2	LV R3	LV R4	LV R5	SR R1	SR R2	SR R3	
Arabinose	-	-	-	-	-	-	-	-	-	-	-
Cellobiose	+	+	+	+	-	+	+	+	+	+	+
Fructose	+	+	+	+	+	-	-	+	+	+	+
Galactose	+	+	-	-	+	+	+	+	+	+	+
Glucose	+	+	+	+	+	-	-	-	-	-	-
Glycerol	-	-	-	-	-	+	+	-	-	-	-
Inulin	+	-	+	+	-	-	-	+	+	+	+
Lactose	+	**	-	-	+	-	+	+	+	+	+
Maltose	+	+	+	+	-	+	+	-	-	-	-
Mannitol	-	-	-	-	+	-	-	+	+	+	+
Mannose	+	+	+	+	+	+	+	+	+	+	+
Raffinose	+	+	+	+	+	-	-	+	+	+	+
Ribose	-	-	-	-	-	-	-	+	+	+	+
Sorbitol	-	-	-	-	-	-	-	-	+	+	+
Starch	+	-	-	-	-	-	-	+	+	+	+
Sucrose	+	+	+	+	+	+	+	+	+	+	+
Xylose	-	-	-	-	-	-	-	-	-	-	-

* Two of the white pigmented *S. bovis* isolates did not ferment inulin; ** one *S. equinus* isolate grew on lactose.

WO 01/02008

PCT/AU00/00805

70

Table 3 Lactate production (mmol/l) by *S. ruminantium* (SR R1, SR R2 and SR R3) cultures after 24h of anaerobic incubation in a broth of basal medium 10 with glucose or starch added at 0.5% at 39°C.

	Type A		Type B	
Isolates →	<i>S. ruminantium</i> (SR R1)		<i>S. ruminantium</i> (SR R2 and SR R3)	
Carbohydrate	Glucose	Starch	Glucose	Starch
L-Lactate	23.7	0.0	20.1	15.5
D-Lactate	0.0	0.0	19.9	15.1
Total (mmol/l)	23.7	0.0	40.0	26.6
Initial pH	6.91	7.20	6.91	7.20

WO 01/02008

PCT/AU00/00805

71

Table 4 Lactate production (mmol/l) by *S. bovis* and *Clostridium-like vitulinus* cultures after 24h of anaerobic incubation in a broth of basal medium 10 with glucose or starch added at 0.5% at 39°C. The pH of BM 10 with glucose was 6.92 and with starch was 7.20.

Isolates	<i>S. bovis</i> * (Sb R1, Sb R2, Sb R3)		<i>C-like vitulinus</i> (LV R1, LV R2, LV R4, LV R5)		<i>C-like. vitulinus</i> (LV R3)	
	Glucose	Starch	Glucose	Starch	Glucose	Starch
L-Lactate	41.1	42.8	0.0	0.0	20.7	0.0
D-Lactate	0.0	0.0	39.3	0.0	20.6	0.0
Total (mmol/l)	41.1	42.8	39.3	0.0	41.3	0.0

* Mean values \pm SE.

WO 01/02008

PC1. 00/00000

72

Table 5 Effect of virginianycin (VM) concentration on the growth of different bacterial isolates of *S. bovis*, *Clostridium*-like *vitulinus* and *S. rumicantium* in a broth of medium 10 with glucose added at 0.5%.

Bacterial isolate	VM level (µg/ml)											
	0		2		4		6		8			
	24	48	24	48	24	48	24	48	24	48	24	48
Incubation period (h) →												
<i>S. bovis</i> and <i>S. equinus</i> (orange pigmented)	+	+	-	-	-	-	-	-	-	-	-	-
<i>S. bovis</i> and <i>S. equinus</i> (white pigmented)	+	+	-	-	-	-	-	-	-	-	-	-
<i>Clostridium</i> -like <i>vitulinus</i> (LV R1)	+	+	-	+	-	+	-	+	-	+	-	+
<i>Clostridium</i> -like <i>vitulinus</i> (LV R2)	+	+	+	+	-	+	-	+	-	+	-	+
<i>Clostridium</i> -like <i>vitulinus</i> (LV R3)	+	+	+	+	-	+	-	+	-	+	-	+
<i>Clostridium</i> -like <i>vitulinus</i> (LV R4)	+	+	+	+	+	+	-	+	-	+	-	+
<i>Clostridium</i> -like <i>vitulinus</i> (LV R5)	+	+	-	+	-	+	-	+	-	+	-	+
<i>S. rumicantium</i> (SR R1, SR R2 and SR R3)	+	+	+	+	+	+	+	+	+	+	+	+

* 24-h incubation, ** 48 + h incubation.

References

- Aihua Liu (1999) Reducing the risk of lactic acidosis in sheep by probiotic lactate utilising and starch fermenting bacteria. PhD Thesis. University of New England, Armidale, NSW 2351, Australia.
- Altschul, S.F., Gish W., Miller W., Myers E.W., and Lipman D.J. (1990). Basic local alignment search tool. *Journal of Molecular Biology* **215**, 403-410.
- Bryant M.P. 1956. The characteristics of strains of *Selenomonas* as isolated from bovine rumen contents. *Journal of Bacteriology* **72**, 162-167.
- Caldwell D.R. and Bryant M.P. 1966. Medium without rumen fluid for nonselective enumeration and isolation of rumen bacteria. *Applied Microbiology* **14**, 794-801.
- Courtney D.A. and Seirer R.C. 1996. Supplementary feeding of grain to cattle with virginiamycin to reduce the risk of acidosis. *Animal Production in Australia* **21**, 344.
- De Man J.C., Rogosa M. and Sharp M.E. 1960. A medium for the cultivation of lactobacilli. *Journal of Applied Bacteriology* **23**, 130-135.
- Dojka, M.A., Hugenholtz P., Haack S.K., and Pace N.R. (1998). Microbial diversity in a hydrocarbon- and chlorinated-solvent-contaminated aquifer undergoing intrinsic bioremediation. *Applied and Environmental Microbiology* **64**, 3869-3877.
- Godfrey S.I., Rowe J.B., Speijers E.J. and Toon W. 1993. Lupin, barley, or barley plus virginiamycin as supplement for sheep at different feeding intervals. *Australian Journal of Experimental Agriculture* **33**, 135-140.
- Godfrey S.I., Rowe J.B., Thorniley G.R., Boyce G.R. and Speijers E.J. 1995. Virginiamycin to protect sheep fed wheat, barley or oats from grain poisoning under simulated drought feeding conditions. *Australian Journal of Agricultural Research* **46**, 393-401.
- Hardie J.M. 1986. Other streptococci. In: *Bergey's Manual of Systematic Bacteriology*. Volume 2. Ed.: Peter H.A. Sneath. pp. 1068-1069. Williams & Wilkins, Baltimore, USA.
- Huntington G.B. 1993. Nutritional problems related to the gastro-intestinal tract: Acidosis. In: D.C. Church (Ed.) *The ruminant animal, Digestive physiology and nutrition*. pp. 474-480. Waveland Press, Inc. Illinois, U. S. A.
- JETACAR (1999) The use of antibiotics in food-producing animals: antibiotic-resistant bacteria in animals and humans. Report of the Joint Advisory Committee on Antibiotic Resistance. Commonwealth of Australia [ISBN 1 86496 061 2]

Lane, D.J. (1991). 16S/23S sequencing. In: Nucleic Acids Techniques in Bacterial Systematics. Eds.: Stackebrandt, E. and Goodfellow, M. pp. 115-175, John Wiley and Sons, New York.

Leedle, J.A.T. (1990) Ruminant Bacterium for preventing acute lactic acidosis. Patent US487491, EP594590.

Mori, Y., Takahashi, T., Katsumi, M., Katoh, K., Hiramune, T. and Kikuchi, N. 1997. Phylogenetic analyses of swine isolates of *Streptococcus dysgalactiae* based on 16S rDNA sequence. (unpublished, submitted to the DDBJ/EMBL/GenBank database on March 31, 1997, Accession AB002482).

Nagaraja T.G., Avery T.B., Bartley E.E., Galitzer S.J. and Dayton A.D. 1981. Prevention of lactic acidosis in cattle by lasalocid or monensin. *Journal of Animal Science* 53 (1), 206-216.

Nagaraja T.G., Avery T.B., Galitzer S.J. and Harmon D.L. 1985. Effect of ionophore antibiotics on experimentally induced lactic acidosis in cattle. *American Journal of Veterinary Research* 46 (12), 2444-2452.

Nagaraja T.G. and Taylor M.B. 1987. Susceptibility and resistance of ruminal bacteria to antimicrobial feed additives. *Applied and Environmental Microbiology* 53, 1620-1625.

Nagaraja T.G., Godfrey S.I., Winslow S.W. and Rowe J.B. 1995. Responses in ciliated protozoa and rumen fermentation in sheep with barley plus virginiamycin. *Australian Journal of Agricultural Research* 46, 1137-1147.

Nelms, L.F., Odellson, D.A., Whitehead, T.R. and Hespell, R.B. 1995. Differentiation of ruminal and human *Streptococcus bovis* strains by DNA homology and 16s rRNA probes. *Current Microbiology* 31, 294-300.

Rogers J.A., Branine M.E., Miller C.R., Wray M.I., Bartle S.J., Preston R.L., Gill D.R., Pritchard R.H., Stilborn R.P. and Bechtol D.T. 1995. Effects of dietary virginiamycin on performance and liver abscess incidence in feedlot cattle. *Journal of Animal Science* 73, 9-20.

Rowe, J.B. 1997. 'Acidic gut syndrome': is it a problem for animals and humans? In: Recent Advances in Animal Nutrition in Australia. (eds. J.L. Corbett, M. Choct, J.V. Nolan, J.B. Rowe). pp. 47-55.

Russell, J.B. and Baldwin, R.L. 1978. Substrate preference in rumen bacteria: evidence of catabolite regulatory mechanisms. *Applied and Environmental Microbiology* 36, 319-329.

Russell, J.B. and Baldwin, R.L. 1979. Comparison of maintenance energy expenditures and growth yields among several bacteria grown on continuous culture. *Applied and Environmental Microbiology* 37, 537-543.

Strunk, O., Gross O., Reichel B., May M., Herman S., Struckmann N., Nonhoff B.,
5 Lenke M., Vilbig A., Ludwig T., Bode A., Schleifer K-H, and Ludwig W. Program available from <http://www.mikro.biologie.uni-muenchen.de> (Unpublished).

Thorniley G.R.; Rowe J.B.; Cowcher P.C. and Boyce M.D. 1998. A single drench of virginiamycin to increase safety of feeding grain to sheep. *Australian Journal of Agricultural Research* 49, 899-906.

10 Wallace R.J. 1996. Rumen microbiology and efficiency of digestion. In: Milk composition, production and biotechnology. *Biotechnology in agriculture series 18*, 465-487.

Yanke L.J. and Cheng K.-J. 1998. A method for the selective enumeration and isolation of ruminal *Lactobacillus* and *Streptococcus*. *Letters in Applied Microbiology* 26, 248-
15 252.

Claims

1. A vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.
2. The vaccine of claim 1, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.
3. The vaccine of claim 1 or 2, wherein the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).
4. The vaccine of any one of claims 1 to 3, wherein the vertebrate is selected from the group consisting of a monogastric, herbivore, human or ruminant animal.
5. The vaccine of any one of claims 1 to 4, wherein said vaccine comprises live or dead intact cells of at least one of said microorganisms.
6. The vaccine of any one of claims 1 to 4, wherein said vaccine comprises outer membrane and associated proteins of at least one of said microorganisms.
7. The vaccine of any one of claims 1 to 6, wherein the fragment or fragments of the microorganism is present in the vaccine as an immunogenic polypeptide, glycopeptide or the like.

8. The vaccine of any one of claims 1 to 7, wherein the vaccine is formulated for administration via intramuscular, subcutaneous, inhalation, topical or other parenteral route.

9. A pharmaceutical composition for the prevention of lactic acidosis in a vertebrate comprising at least one isolated microorganism capable of producing lactic acid within the gut of a vertebrate, or fragment or fragments thereof, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

10. The pharmaceutical composition of claim 9, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

11. The pharmaceutical composition of claim 9 or 10, wherein the microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

12. The pharmaceutical composition according to any one of claims 9 to 11, wherein the microorganism is provided as live cells, attenuated cells, killed whole cells, cell lysate, crude antigen mixture or purified antigen or antigens from the microorganism.

13. The pharmaceutical composition according to any one of claims 9 to 12, wherein the microorganism, and/or fragment or fragments thereof, is present as outer membrane and associated proteins of said microorganism.

14. The pharmaceutical composition according to any one of claims 9 to 13, wherein the fragment or fragments of the microorganism is present as an immunogenic polypeptide or glycopeptide, or the like.

15. The pharmaceutical composition according to any one of claims 9 to 14, further comprising at least one cytokine.

16. A method for inducing an immune response against lactic acidosis in a vertebrate, comprising administering to said vertebrate an immunologically effective amount of the vaccine in accordance with any one of claims 1 to 8, or a pharmaceutical composition in accordance with any one of claims 10 to 15.

17. A method according to claim 16, further comprising administering at least one cytokine.

18. A method for inducing an immune response against lactic acidosis in a vertebrate, comprising administering to said vertebrate an immunologically effective amount of the vaccine according to any one of claims 1 to 8.

19. A method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of the vaccine in accordance with any one of claims 1 to 8, or a pharmaceutical composition in accordance with any one of claims 10 to 15.

20. The method of claim 19, wherein said method further comprises the administration of an active agent.

21. A method for the treatment and/or prophylaxis of lactic acidosis in a vertebrate in need of said treatment and/or prophylaxis, wherein said method comprises administering to said vertebrate a therapeutically effective amount of an active agent capable of preventing or controlling lactic acid accumulation in the gut of a vertebrate, and wherein said lactic acid is produced by at least one microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

22. The method of claim 21, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *virulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

23. The method of claim 21 or 22, wherein said microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3)

WO 01/02008

PCT. 00/00805

79

(NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

24. The method of any one of claims 19 to 23, wherein the active agent is used in conjunction with a vaccine according to any one of claims 1 to 8.

25. The method of any one of claims 19 to 24, wherein the active agent is selected from the group consisting of: antibiotics, enzyme preparations, clay preparations, compounds which slow the digesta flow, prebiotics and probiotics.

26. The method of claim 25, wherein the antibiotic is active against gram-positive lactic acid producing microorganisms.

27. The method of claim 25, wherein the enzyme preparation is active against lactic acid producing gram-negative bacteria.

28. The method of claim 25, wherein the clay preparation is active against lactic acid producing Gram-negative or Gram positive bacteria.

29. The method of claim 25, wherein the compounds which slow digesta flow rate are indirectly active against lactic acid producing gram-negative bacteria.

30. The method of claim 29, wherein the compounds which slow digesta flow rate are selected from the group consisting of biologically active peptides (BAP), compounds active on the autonomic nervous system, 5HT agonists/antagonists, motilin antagonists, NO promoters, and dopamine.

31. The method of claim 25, wherein the probiotic preparations include bacteria selected from the group consisting of: *Megasphaera*, *Veillonella*, *Selenomonas*, *Propionibacterium*, *Anaerovibrio* and *Peptococcus*.

32. The method of claim 31, wherein the probiotic preparations include yeast and mycelial preparations capable of utilising lactic acid, and converting lactic acid to volatile fatty acids and other end products.

33. An isolated nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of: SEQ ID Nos 1-7.

34. A nucleic acid molecule analogue of the polynucleotide sequence of claim 33, wherein said analogue has at least 85% homology to said polynucleotide sequence.

WO 01/02008

PC1...J00/00805

80

35. A nucleic acid molecule oligonucleotide fragment of the polynucleotide sequence according to claim 33 or 34.

36. A vector comprising the nucleic acid molecule according to any one of claims 33 to 35.

37. The vector of claim 36, wherein the vector is selected from the group consisting of: viral, plasmid, bacteriophage, phagemid, cosmid, bacterial artificial chromosome, and yeast artificial chromosome.

38. A host cell transformed with the vector of claim 36 or claim 37.

39. An antibody raised against at least one lactic acid producing microorganism, wherein said microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

40. The antibody of claim 39, wherein the microorganism is selected from the group consisting of: *Streptococcus equinus*, *Clostridium*-like *vitulinus*, *Selenomonas ruminantium*, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Streptococcus bovis* SbR1 and non-slime producing lactic acid bacterial isolates LAB02, LAB06 and LAB08.

41. The antibody of claim 39 or 40, wherein said microorganism is selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

42. A vaccine comprising at least one antibody according to any one of claims 39 to 41, together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.

43. A diagnostic kit for the detection of microorganisms having a role in lactic acidosis in a vertebrate, said kit comprising at least one antibody according to any one of claims 39 to 41, together with a diagnostically acceptable carrier and/or diluent.

44. The diagnostic kit of claim 43 comprising:

(a) a first container containing at least the antibody (or fragment thereof) according to any one of claims 39 to 41, and;

(b) a second container containing a conjugate comprising a binding partner of the antibody (or fragment thereof), together with a detectable label.

45. The diagnostic kit of claim 44, wherein said first container further contains antibodies selected from the group consisting of: antibodies capable of detecting at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli and antibodies capable of detecting *Streptococcus bovis* (strain Sb-5).

46. A method for screening for the presence of microorganisms having a role in acidosis in a vertebrate comprising:

(a) contacting a sample from the gut of a vertebrate with the antibody (or fragment thereof) according to any one of claims 39 to 41, and

(b) detecting the presence of the antibody (or fragment thereof) bound to microorganisms having a role in acidosis.

47. A method for screening for the presence of microorganisms having a role in acidosis in a vertebrate comprising:

(a) contacting a nucleic acid sample from a microorganism is selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, and

(b) detecting hybridisation between the nucleic acid sample and the probe sequence.

48. The method of claim 47 wherein the nucleic acid probe corresponds to a portion of at least one of the polynucleotide sequences according to any one of claims 33 to 34, which is capable of selectively hybridising to nucleic acid from a sample.

49. The method of claim 47 or 48, wherein the nucleic acid probe corresponds to a probe mix, comprising a portion of the polynucleotide sequence according to any one of claims 34 to 35 which is capable of selectively hybridising to nucleic acid from a sample, together with an isolated nucleic acid molecule comprising a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of at least one lactic acid producing strain selected from *Streptococcus bovis* or lactobacilli, or a polynucleotide sequence capable of selectively hybridising to the nucleic acid (or portion thereof) of the microorganism strain *Streptococcus bovis* (strain Sb-5).

50. A method for screening for potential therapeutic agents for the treatment of lactic acidosis in a vertebrate, said method comprising

WO 01/02008

PCA/J00/00805

82

(a) contacting the potential therapeutic agent with a microorganism selected from the group consisting of: *Clostridium*-like species, *Prevotella*-like species, *Bacteroides*-like species, *Enterococcus*-like species, *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates, and

(b) detecting an effect of the therapeutic agent on said microorganism.

51. The method of claim 50, wherein said therapeutic agent alters the lactic acid production pathway in at least one of said microorganisms.

52. An isolated culture of at least one microorganism selected from the group consisting of: *Streptococcus bovis* (SbR1) (NM99/04455), *Streptococcus equinus* (SER1) (NM99/04456); *Streptococcus equinus* (SER2) (NM99/04457); *Selenomonas ruminantium* (SRR1) (NM99/04458); *Selenomonas ruminantium* (SRR3) (NM99/04460); *Clostridium*-like *vitulinus* (LVR3) (NM99/04461); *Clostridium*-like *vitulinus* (LVR4) (NM99/04462), *Prevotella*-like isolates LAB01 (NM00/12630) and LAB03 (NM00/12632), *Bacteroides*-like isolate LAB07 (NM00/12636), *Enterococcus*-like isolate LAB05 (NM00/12634), *Streptococcus bovis* (SbR1), non-dextran slime producing *Streptococcus* isolate LAB04 (NM00/12633) and non-slime producing lactic acid bacterial isolates LAB02 (NM00/12631), LAB06 (NM00/12635) and LAB08 (NM00/12637).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02008 A1(51) International Patent Classification⁷: A61K 39/02,
39/08, 39/09, 39/116, 35/74, C12N 15/11, 1/20(74) Agent: SPRUSON & FERGUSON; GPO Box 3898, Syd-
ney, NSW 2001 (AU).

(21) International Application Number: PCT/AU00/00805

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 3 July 2000 (03.07.2000)

(25) Filing Language: English

(26) Publication Languages: English

(30) Priority Data: PQ 1376 2 July 1999 (02.07.1999) AU

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): THE
UNIVERSITY OF NEW ENGLAND (AU/AU): Armidale, NSW 2351 (AU).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ROWE, James,
Baber, [AU/AU]; 411 Rockvale Road, Armidale, NSW
2350 (AU). AL JASSIM, Rafat, A., M. [AU/AU]; School
of Animal Studies, The University of Queensland, Gatton
Campus, Gatton QLD 4343 (AU). *AUX*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CONTROL OF ACIDOSIS

(57) Abstract: The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: *Clostridium*-like species; *Prevotella*-like species; *Bacteroides*-like species; *Enterococcus*-like species; *Selenomonas* species, non-dextran slime producing *Streptococcus* species and non-slime producing lactic acid bacterial isolates.

WO 01/02008 A1

WO 01/02008

PCT/JP00/00805

1/1




Fig. 1

U.S. PATENT

OFFICE OF THE COMMISSIONER OF PATENTS

TO 00267733275

P.01 03

NO. 01300

P. 3/9

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
(Page 1)**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

"Control of Acidosis"

the specification of which ☐ is attached hereto ☒ was filed on March 2, 2001 as United States Application No. 09/786,253 or PCT International Application No. _____ and was amended on _____ (if applicable).

I hereby state I have reviewed and understand the contents of the above-identified specification, including claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefit under 35 U.S.C. §119(a) or §365(b), of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designates at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT (international) application having a filing date before that of the application on which priority is claimed.

<u>Country</u>	<u>Application No.</u>	<u>Filed (Day/Mo./Yr.)</u>	<u>(Yes/No) Priority Claimed</u>
Australia	PQ1376	2 July 1999	Yes

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>Application No.</u>	<u>Filed (Day/Mo./Yr.)</u>	<u>Status (Patented, Pending, Abandoned)</u>
PCT/AU00/00805	3 July 2000	Abandoned

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

McDonnell Boehnen Hulbert & Berghoff

Customer Number: 020306

Principal attorney: Michael S Greenfield

Telephone Number: 312-913-0001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

[R:\LIBU\15851.doc]

JUL 06 '01 07:43PM SPRUSON & FERGUSON 92615486

SEQUENCE LISTING

PTO/PCT Rec'd 15 AUG 2001

<110> Rowe, James B.
Al Jassim, Rafat A

<120> Control of Acidosis

<130> 01-179

<140> 09/786253

<141> 2000-07-03

<150> PCT/AU00/00805

<151> 1999-07-02

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 1470

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism: Clostridium-like
vitulinus

<220>

<221> misc_feature

<222> (21)

<223> n is unknown

<400> 1

gacgaacgct ggcggcgctgc ntaatacatg caagtagaac gctgaagact ttagcttgct 60
aaagttggaa gagttgcaa cgggtgagta acgcgtaggt aacctgccta ctacgggggg 120
ataactattg gaaacgatag ctaataccgc ataacagcat ttaacacatg ttagatgctt 180
gaaaggagca attgcttcac tagtagatgg acctgcgttg tattagctag ttggtgaggt 240
aacggctcac caaggcgacg atacatagcc gacctgagag ggtgatcggc cacactggga 300
ctgagacacg gccagactc ctacgggagg cagcagtagg gaatcttcgg caatgggggc 360
aaccctgacc gagcaacgcc gcgtgagtga agaaggtttt cggatcgtaa agctctgttg 420
taagagaaga acgtgtgtga gagtggaag ttcacacagt gacggtaact taccagaaag 480
ggacggctaa ctacgtgccg gcagccgagg taatacgtag gtcccgagcg ttgtccggat 540
ttattgggag taaagcgagc gcaggcgggt taataagtct gaagttaaag gcagtggctt 600
aaccattgtt cgctttggaa actgttagac ttgagtgcag aaggggagag tgggaattcca 660
tgtgtagcgg tgaaatgcgt agatatatgg aggaacaccg gtggcgaaag cggtctcttg 720
gtctgtaact gacgctgagg ctcgaaagcg tggggagcaa acaggattag ataccctggt 780
agtcacgccc gtaaacgatg agtgctaggt gttaggccct ttccggggct tagtgccgca 840

gctaacgcat taagcactcc gcctggggag tacgaccgca aggttgaaac tcaaaggaat 900
 tgacgggggc ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac gcgaagaacc 960
 ttaccaggtc ttgacatccc gatgctattc ctagagatag gaagtttctt cggaacatcg 1020
 gtgacagggtg gtgcatgggtt gtcgtcagct cgtgtcgtga gatgttgggt taagtccccg 1080
 aacgagcgca acccctattg ttagttgcca tcattaagtt gggcactcta gcgagactgc 1140
 cggtaataaa ccggaggaag gtggggatga cgtcaaatca tcatgcccct tatgacctgg 1200
 gctacacacg tgctacaatg gttggtacaa cgagtcgcga gtcggtgacg gcaagcaaatt 1260
 ctcttaaagc caatctcagt tcggattgta ggctgcaact cgcctacatg aagtcggaat 1320
 cgctagtaat cgcggtacg cagcgcgcgg tgaatacgtt cccgggcctt gtacacaccg 1380
 cccgtcacac cagcagagtt tgtaacaccc gaagtcggtg aggtaacctt ttggagccag 1440
 ccgcctaagg tgggatagat gattgggggtg 1470

<210> 2

<211> 666

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism: Clostridium-like
 vitulinus

<400> 2

ccggatttat tgggcgtaaa gcgagcgcag gcggtttaat aagtctgaag ttaaaggcag 60
 tggtttaacc attgttcgct ttggaaactg ttagacttga gtgcagaagg ggagagtggg 120
 attccatgtg tagcgggtgaa atgcgtagat atatggagga acaccggtgg cgaaagcggc 180
 tctctgggtc gtaactgacg ctgaggctcg aaagcgtggg gagcaaacag gattagatac 240
 cctggtagtc cagcccgtaa acgatgagtg ctagggtgta ggccctttcc ggggcttagt 300
 gccgcagcta acgcattaag cactccgcct ggggagtagc accgcaagggt tgaaactcaa 360
 aggaattgac gggggcccgc acaagcgggt gagcatgtgg ttttaattcg agcaacgcga 420
 agaaccttac caggtcttga catcccgatg ctatttctag agataggaag tttcttcgga 480
 acatcgggtg caggtgggtg atggttgctg tcagctcgtg tcgtgagatg ttgggttaag 540
 tcccgcacg agcgcacccc ctattgttag ttgccatcat taagttgggc actctagcga 600
 gactgccggt aataaaccgg aggaagggtg ggatgacgtc aaatcatcat gccccttatg 660
 acctgg 666

<210> 3

<211> 662

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism: Clostridium-like
 vitulinus

<400> 3

atttattggg cgtaaagcga gcgcaggcgg ttttaataagt ctgaagttaa aggcagtggc 60
 ttaaccattg ttcgctttgg aaactgttag acttgagtgc agaaggggag agtggaattc 120
 catgtgtagc ggtgaaatgc gtagatatat ggaggaacac cgggtggcgaa agcggctctc 180

tggctctgtaa	ctgacgctga	ggctcgaaag	cgtggggagc	aaacaggatt	agataccctg	240
gtagtccacg	ccgtaaacga	tgagtgctag	gtgttaggcc	ctttccgggg	cttagtgccg	300
cagctaacgc	attaagcact	ccgcttgggg	agtacgaccg	caaggttgaa	actcaaagga	360
attgacgggg	gcccgcacaa	gcggtggagc	atgtggttta	attcgaagca	acgcgaagaa	420
ccttaccagg	tcttgacatc	ccgatgctat	ttctagagat	aggaagtttc	ttcggaacat	480
cggtgacagg	tgggtgcatgg	ttgtcgtcag	ctcgtgtcgt	gagatgttgg	gttaagtccc	540
gcaacgagcg	caacccttat	tgttagttgc	catcattaag	ttggggactc	tagcgagact	600
gccggtaata	aaccggagga	aggtggggat	gacgtcaaat	catcatgccc	cttatgacct	660
gg						662

```
<210> 4
<211> 1451
<212> DNA
<213> Unknown
```

<220>
<223> Description of Unknown Organism: Clostridium-like
vitulinus

<400>	> 4						
gatgaacgct	ggcggcgctgc	ctaatacatg	caagtcgaac	gggaatcttc	ggattccagt	60	
ggcgaacggg	tgaggaatac	ataggttaacc	tgccctccg	agggggacaa	cagacggaaa	120	
catctgctaa	gaccgcatag	ccacagggaa	ggcatcttcc	ctgtgccaaa	tgctctttcg	180	
gggacagcgg	ggggatggac	ctatgccgca	ttagctggtt	ggcggggcaa	cggcccacca	240	
aggcgcagat	gcgtagccgg	cctgagaggg	cggacggcca	cactgggact	gagacacggc	300	
ccagactcct	acgggaggca	gcagtaggga	attttcggca	atgggggaaa	ccctgaccga	360	
gcaacgcgc	gtgaacgatg	aaggccttcg	ggtcgtaaag	ttctgttgcg	aagggaagaac	420	
gccggtgtca	ggaaatgggc	gccgggtgac	ggtacttcgc	atagaaagcc	acggctaact	480	
acgtgccagc	agccgcggta	atacgtaggt	ggcgcgcgtt	atccggaatc	attgggcgta	540	
aagagggagc	aggcggcgat	acaggtctgt	ggtgaaattc	cgaagctaaa	cttcggccag	600	
ccaaagaaac	cggatcgcta	gagtgcggaa	gaggatcgtg	gaattccatg	tgtagcggtg	660	
aaatgcgtag	atatatggag	gaacaccagt	ggcgaaggcg	acggtctggg	ccgcaactga	720	
cgctcattcc	cgaaagcgtg	gggagcaaat	aggattagat	accctagtag	tccacgccgt	780	
aaacgatcga	tactaagtgt	cgggggtcaa	acctcggtgc	tggagtcaac	gcaataagta	840	
tcgcgcctga	gtagtacgtt	cgcaagaatg	aaactcaaag	gaattgacgg	gggcccgcac	900	
aagcggtgga	gcatgtggtt	taattcgaag	caacgcgaag	aaccttacca	ggtcttgaca	960	
tcgatccaaa	agggacggag	acgtcccat	agctatggag	aagacaggtg	gtgcatggtt	1020	
gtcgtcagct	cgtgtcgtga	gatgttgggt	taagtccgc	aacgagcgca	acctctgtcg	1080	
ccagttgcca	gcattgagtt	ggggactctg	gcgagactgc	ctctgcaagg	aggaggaagg	1140	
cggggatgac	gtcaaatcat	catgccctt	atgacctggg	ccacacacgt	gctacaatgg	1200	
acggagcaga	gggaagcgaa	gcggcgacgc	caagcggatc	ccagaaaccc	gttctcagtt	1260	
cggactgcag	tctgcaactc	gactgcacga	agctggaatc	gctagtaatc	gcggatcagc	1320	
atgccgcggt	gaatacgttc	tcgggccttg	tacacaccgc	cgctcacacc	atgagagtcg	1380	
gcaacacccg	aagccgggtg	ctcaaccctt	cggggaggga	gctgtctaag	gtggggccga	1440	
tgattgggggt	g					1451	

```
<210> 5
<211> 1451
```

<213> Unknown

 $\langle 220 \rangle$

<223> Description of Unknown Organism: Clostridium-like
vitulinus

<400> 5

gatgaacgct	ggcggcgctgc	ctaatacatg	caagtcgaaac	gggaatcttc	ggattccagt	60
ggcgaacggg	tgaggaatac	ataggtaacc	tgccctccg	agggggacaa	cagacggaaa	120
catctgctaa	gaccgcatag	ccacagggaa	ggcatcttcc	ctgtgccaaa	tgtcctttcg	180
gggacagcgg	ggggatggac	ctatgccgca	ttagctggtt	ggcggggcaa	cggcccacca	240
aggcgacgat	gcgtagccgg	cctgagaggg	cggacggcca	cactgggact	gagacacggc	300
ccagactcct	acgggaggca	gcagtaggga	attttcggca	atgggggaaa	ccctgaccga	360
gcaacgccgc	gtgaacgatg	aaggccttcg	ggtcgtaaag	ttctgttgcg	aaggaagaac	420
gccggtgtca	ggaaaatgggc	gccgggtgac	ggtacttcgc	atagaaaagcc	acggctaact	480
acgtgccagc	agccgcggta	atacgtaggt	ggcgagcggt	atccggaatc	attgggcgta	540
aagagggagc	aggcggcgat	acaggtctgt	ggtgaaattc	cgaagctaaa	cttcggccag	600
ccaaagaaac	cggatcgcta	gagtgcggaa	gaggatcggt	gaattccatg	tgtagcgggtg	660
aaatgcgtag	atatatggag	gaacaccagt	ggcgaaggcg	acggtctggg	ccgcaactga	720
cgctcattcc	cgaaaagcgtg	gggagcaaat	aggattagat	accctagtag	tccacgccgt	780
aaacgatcga	tactaagtgt	cgggggtcaa	acctcggtgc	tggagtcaac	gcaataagta	840
tcgcgcctga	gtagtacgtt	cgcaagaatg	aaactcaaag	gaattgacgg	gggcccgcac	900
aagcggtgga	gcatgtgggt	taattcgaag	caacgcgaag	aaccttacca	ggtcttgaca	960
tcgatccaaa	agggacggag	acgtccccat	agctatggag	aagacaggtg	gtgcatgggt	1020
gtcgtcagct	cgtgtcgtga	gatgttggg	taagtcccg	aacgagcgca	accctgtcg	1080
ccagttgcca	gcattgagtt	ggggactctg	gcgagactgc	ctctgcaagg	aggaggaagg	1140
cggggatgac	gtcaaatac	catgccccct	atgacctggg	ccacacacgt	gctacaatgg	1200
acggagcaga	gggaagcgaa	gcggcgacgc	caagcggatc	ccagaaaacc	gttctcagtt	1260
cggactgcag	tctgcaactc	gactgcacga	agctggaatc	gctagtaatc	gcggatcagc	1320
atgccgcggt	gaatacgttc	tcgggccttg	tacacaccgc	ccgtcacacc	atgagagtcg	1380
gcaacaccgc	aagccgggtg	ctcaaccctc	cggggaggga	gctgtctaag	gtggggccga	1440
tgattgggg	g					1451

<210> 6

<211> 1483

<212> DNA

<213> Unknown

<220>

<223> Description of Unknown Organism: Clostridium-like
vitulinus

<400> 6

gacgaacgct	ggcggcgctgc	ttaacacatg	caagtcgaac	gaggygattt	waagcttgct	60
tagatgagtc	gagtggcaaa	cgggtgagta	acgcgtagac	aacctgccgc	aaagatgggg	120
acaacagtc	gaaaggactg	ctaataccga	atgttgtcag	attcccgcat	gggagactga	180
ttaaagatgg	cctctacttg	taagctatcg	ctttgcgatg	ggtctgcgct	tgattagcta	240

cgggagccag cggtcttaagg tgggggcat gactggggtg

1000

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 27f primer

<400> 8

agagtttgat cctggctcag

20

<210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 1492r primer

<400> 9

ggttaccttg ttacgact

18

<210> 10

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 530f primer

<400> 10

gtgccagcmg ccgcgg

16

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 519r primer

<400> 11

gwattaccgc ggckgctg

18

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 907r primer

<400> 12

ccgtcaattc mtttragttt

20

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: 926f primer

<400> 13

aaactyaaak gaattgacgg

20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 01-179) 528 Rec'd PCT/PTO 02 MAR 2001

In the Application of:

James Baber Rowe, et al.

Serial No.: U.S. Nat'l Phase of PCT/AU00/00805

Int'l Filing Date: July 3, 2000

For: Control Of Acidosis

Examiner: TBA

Group Art Unit: TBA

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please consider the following amendments and remarks before examination on the merits.

In the claims:*Please amend the claims as follows:*

Amend claims 3-8 and 18 to depend from claim 1 only.

Amend claims 11-15 to depend from claim 9 only.

Amend claim 16 by deleting "claims 1 to 8" in the third line of the claim and inserting -claim 1- therefor.

Amend claim 16 by deleting "claims 10 to 15" in the forth line of the claim and inserting -claim 10- therefor.

Amend claim 18 by deleting "claims 1 to 8" in the fourth line of the claim and inserting -claim 1- therefor.

Amend claim 19 by deleting "claims 10 to 15" in the fifth line of the claim and inserting -claim 10- therefor.

Amend claim 23 to depend from claim 21 only.

Amend claims 24 and 25 to depend from claim 19 only.

Amend claims 35 and 36 to depend from claim 33 only.

Amend claim 38 to depend from claim 36 only.

Amend claims 41-43 to depend from claim 39 only.

Amend claim 44 by deleting in part (a) "any one of claims 39 to 41" and inserting - claim 39- therefor.

Amend claim 46 by deleting in part (a) "any one of claims 39 to 41" and inserting - claim 39- therefor.

Amend claim 48 by deleting "according to any one of claims 33 to 34" in the second line of the claim and inserting -selected from the group consisting of: SEQ. ID. Nos.: 1-7- therefor.

Amend claim 49 by deleting "47 or 48" in the first line of the claim and inserting -47- therefor.


Amend claim 49 by deleting "according to any one of claims 34 to 35" bridging the second and third lines of the claims and insert -having at least 85% homology to a polynucleotide sequence selected from the group consisting of SEQ. ID. Nos.: 1-7- therefor.

REMARKS

The foregoing amendments to the afore-mentioned claims remove multiple dependencies to reduce the cost of filing. Enclosed herewith are the complete amended claims set and a redline version.

If there are any questions or comments regarding this Preliminary Amendment or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Respectfully submitted,



Michael S. Greenfield

Registration No. 37,142

McDonnell Boennen Hulbert & Berghoff

300 South Wacker Drive

Chicago, IL 60606

Telephone: 312-913-0001

Facsimile: 312-913-0002

Date: March 2, 2001